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Abstract

The α7 nicotinic acetylcholine receptor (nAChR) is an ionotropic receptor for the
neurotransmitter acetylcholine and its precursor, choline. Interestingly, α7 nAChR binds
amyloid β 42 (Aβ42) peptide, which has a primary role in Alzheimer’s disease pathology.
Aβ42 peptide forms aggregates and different structural forms elicit different physiological
outcomes. Oligomeric, fibrillar and non-aggregated preparations of Aβ42 were
characterized by atomic force microscopy. Immunoblotting of neuronal cells exposed to
these preparations determined oligomeric aggregates of Aβ42 mediate ERK1/2 intracellular
signalling through α7 nAChR. Cell surface ionotropic receptors are regulated through
endocytosis to maintain the integrity of neurotransmission. Cellular pathways for
endocytosis of α7 nAChR are not fully elucidated. Immunocytochemistry, fluorochromelabelled proteins, and laser-scanning confocal microscopy identified a clathrin-independent
flotillin 1- or caveolin 1α-associated pathway for α7 nAChR endocytosis. These studies
identify a biologically important form of Aβ42 relevant to α7 nAChR intracellular signalling
and an endocytosis pathway for subcellular regulation of α7 nAChR.

KEYWORDS: nicotinic receptor, amyloid β, amyloid oligomer, amyloid fibril, extracellular
signal-regulated kinase mitogen-activated protein kinase, Alzheimer’s disease, endocytosis,
protein trafficking, lysosome, flotillin, caveolin, α-bungarotoxin
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Chapter 1

1

General Review of the Literature

2

1.1 The Cholinergic Neuron
Acetylcholine (ACh) was the first neurotransmitter described (1), it mediates a broad
range of physiological functions in the central (CNS) and peripheral (PNS) nervous
systems. Neurons that synthesize and store ACh are defined as cholinergic (2). ACh
synthesis is catalyzed by the enzyme choline acetyltransferase in the cytoplasm of the
nerve terminal from the substrates choline and acetyl-CoA (3, 4). Newly synthesized
ACh is packaged into secretory vesicles by the vesicular ACh transporter (5 - 11).
Neuronal membrane depolarization leads to the release of vesicular ACh into the
synaptic cleft by a highly-regulated, Ca2+-dependent, complex cascade of events (12 14). Upon release from the nerve terminal, ACh may bind its cognate receptors,
postsynaptic nicotinic or muscarinic receptors or presynaptic nicotinic and muscarinic
autoreceptors (2, 15 - 17). Excess, unbound ACh in the extracellular milieu is cleared by
the enzyme acetylcholinesterase, which hydrolyzes ACh into free acetate and choline
(18). Free choline can be taken up from the extracellular space by the sodiumdependent high-affinity choline transporter, which resides almost exclusively in
cholinergic nerve terminals and facilitates the replenishment of intracellular choline (19,
20). In the PNS, cholinergic neurons innervate skeletal muscle and a number of target
tissues of the sympathetic and parasympathetic branches of the autonomic nervous
system. In the CNS, cholinergic neurons contribute to learning, memory, arousal, and
sleep functions (21).

1.2 Organization of Cholinergic Neurons in the CNS
Cholinergic neurons within the CNS innervate brain structures either intrinsically or
extrinsically (22 - 24). Intrinsic innervation arises from cholinergic interneurons within
the same brain structure, which project their axons locally (23, 24). Innervation of the
striatum and its structures, the islands of Calleja, olfactory tubercle, nucleus accumbens,
and caudate-putamen is intrinsic (22 - 25). Extrinsic innervation connects cholinergic
regions to other brain structures through efferent projections (23, 24, 26). Cholinergic
projection neurons have been divided into two subsystems, the basal forebrain and the
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pontomesencephalic complex (23, 24). Axons from the basal forebrain innervate the
limbic structures and neocortex, while axons from the pontomesencephalic complex
innervate the thalamus and superior colliculus (23, 24). Cholinergic cell groups in the
CNS are diffusely organized and are not confined within traditional nuclear groups, but
are intermixed with non-cholinergic neurons (24). In particular, the nucleus basalis of
Meynert, which provides the primary cholinergic input from the basal forebrain to the
neocortex, contains a mixture of cholinergic, GABAergic, peptidergic, and dopaminergic
neurons (27 - 32). The major groups of cholinergic neurons within the CNS are
designated Ch1 – Ch8 (24). The cholinergic cell groupings within the basal forebrain are
the medial septal nucleus (Ch1), nucleus of the diagonal band of Broca (Ch2), nucleus of
the horizontal band of Broca (Ch3), and the nucleus basalis of Meynert (Ch4) (24). Ch5
and Ch6 designate cholinergic neurons of the pedunculopontine and lateral dorsal
nuclei, respectively; Ch7 designates cholinergic cells of the medial habenula, and Ch8
designates cholinergic neurons in the parabigeminal nucleus (24). Ch1 – Ch4 are major
sources of cholinergic projections to the hippocampus, olfactory bulb, amygdala and
cerebral cortex (24). Ch5 and Ch6 are a source of projections to the thalamic nuclei, Ch7
to the interpenduncular nucleus, and Ch8 to the superior colliculus (24). To a large
extent, cholinergic neurons innervate structures of the brain that are involved in
learning and memory and other higher order functions. Although considerable research
has focused on the role that muscarinic ACh receptors play in cholinergic modulation of
the neural network (33), nicotinic ACh receptors (nAChR) may also contribute
substantially to synaptic plasticity (34).

1.3 Nicotinic Receptors of the CNS
Neuronal nAChRs are distributed widely throughout the brain, with the majority
localized to the pre-synapse or pre-terminal, where they modulate the release of almost
all neurotransmitters (35). They share a common structure comprised of five subunits
that surround a central gated cation pore, permeable to Na+, K+, and Ca2+, which is
opened upon ligand binding (35, 36). They have distinct pharmacological and functional
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properties that are determined by their subunit composition (35). Nine α (α2 – α10)
and three β (β2 – β4) neuronal nAChR subunits have been identified to date (35). The
two major subtypes of nAChR found in the mammalian CNS are heteromeric receptors
containing α4β2 subunits and homomeric receptors comprised of α7 subunits (35).
Each neuronal nAChR subunit has a large hydrophilic extracellular amino-terminus
domain that forms the ACh binding site, followed by three transmembrane domains
(TM1 - TM3), a large intracellular loop, a fourth transmembrane domain (TM4), and a
short extracellular carboxyl-terminus (37) (Figure 1.1). Ligand binding occurs at the
interface between α and adjacent subunits, the heteromeric α4β2 nAChR, with two α4
subunits and three β2 subunits, binds two ligands and the homomeric α7 nAChR, with
five α7 subunits, has five ligand binding sites (35).

1.4 The α7 nAChR
The human α7 nAChR subunit was cloned originally from the SH-SY5Y human
neuroblastoma cell line based on sequence homology with the chick and rat homologue
α-bungarotoxin (αBTX)-binding receptor (38 - 40). αBTX is a subtype-selective nAChR
antagonist isolated from the venom of the Many-banded krait, Bungarus multicinctus
(36, 41). The α7 nAChR is unique in the brain in that it has low binding affinity for
nAChR agonists, such as ACh and nicotine, binds choline as an agonist, and binds αBTX
with high affinity (36). The receptor also has unique biophysical properties, exhibiting
brief channel open times, a large ion conductance, and a high permeability to Ca 2+
relative to Na+ (36). Through high Ca2+ conductance, the α7 nAChR is linked to
activation of a number of intracellular signalling events (42). Although the α7 nAChR
was originally thought to exist only as a homomer in the mammalian CNS, evidence
from heterologous expression studies demonstrate the α7 subunit can also form
functional heteromeric receptors with α5, β2, or β3 subunits (43 - 47). Only very
recently has biochemical evidence emerged in support of the existence of an α7β2containing heteromeric nAChR in the brain (48). The α7β2 nAChR has a pharmacological
profile similar to the α7 nAChR in that its ligand binding properties reflect that of the

5

Figure 1.1 Structure of the nAChR.
The neuronal nAChR is a macromolecule comprised of subunit proteins of similar tertiary
structure. (A) Each nAChR subunit contains a large hydrophilic extracellular amino-terminus,
followed by three transmembrane domains (TM1 - TM3), a large intracellular loop, a fourth
transmembrane domain (TM4), and a short extracellular carboxyl-terminus. (B) Five subunits
combine to a form a functional receptor pentamer. (C) The five subunits surround a central
cation pore that is permeable to Na+, K+, and Ca2+; gating of the cation pore occurs in response
to agonist binding at the interface between α and adjacent subunits. PM, plasma membrane.
Adapted from (35 - 37).
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interface between adjacent α7 subunits (46, 48). While the α7 nAChR is expressed
throughout the brain, the α7β2 nAChR appears to be localized exclusively to basal
forebrain cholinergic neurons (48). This thesis will focus on signalling and molecular
regulation of the homomeric α7 nAChR. Altered α7 nAChR activity is implicated in
cholinergic dysfunction in a number of neurological and psychiatric disorders, including
Alzheimer’s disease (AD) and schizophrenia (34). A 2-base pair deletion polymorphism
in the partial duplication of the α7 nAChR gene has been linked to schizophrenia (49,
50).

1.5 Localization of the α7 nAChR within the CNS
In situ hybridization studies in monkey brain demonstrate widespread expression of
α7 nAChR subunit mRNA throughout the brain, including the neocortex, basal ganglia
and the ventral tegmental area (VTA), with the highest levels found in the hippocampus,
particularly the dentate gyrus (51). [125I]-αBTX binding in adult rat brain provides similar
localization, with moderate binding throughout the cerebral cortex and a high level of
binding in the hippocampus (52). It is evident that the α7 nAChR has a role in mediating
cholinergic input to several brain regions and may have an important role in cholinergic
modulation of synaptic plasticity in the hippocampus (52).

1.6 Subcellular Localization and Function of the α7 nAChR
within the CNS
The subcellular localization and function of α7 nAChR in the brain has largely been
determined through electrophysiology studies and the use of receptor-selective
antagonists. Although there are some examples of α7 nAChR-mediated fast-synaptic
transmission to interneurons in the hippocampus (53 - 55), to a greater extent, the
α7 nAChR serves a modulatory role in the brain by regulating the release of other
neurotransmitters. Presynaptic α7 nAChR directly modulate the release of glutamate in
the hippocampus and VTA, as well as excitatory amino acids in the prefrontal cortex (56
- 58). Evidence that the α7 nAChR participates in cholinergic volume transmission, as
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opposed to synaptic transmission, stems from studies of α7 nAChR localization in the
VTA, where cholinergic terminals are located remotely from αBTX labelling of the
receptor (57). Presynaptic α7 nAChR is also involved in indirect release of dopamine
from the striatum and prefrontal cortex and noradrenaline from the hippocampus (59 61). This can occur through the triggering of glutamate release and/or γ-aminobutyric
acid (GABA) release and GABAergic disinhibition (61). Somatodendritic α7 nAChR in the
hippocampus can depolarize pyramidal neurons to facilitate short- and long-term
potentiation within the hippocampus (62 - 64).

1.7 Signalling of the α7 nAChR
The modulatory role of the α7 nAChR in the CNS likely reflects the permeability of the
ion channel to Ca2+ and local activation of Ca2+-dependent signalling pathways.
Modulation of neurotransmitter release may involve receptor-dependent activation of
ryanodine-sensitive intracellular Ca2+ stores and extracellular signal-regulated kinase 1
and 2 (ERK1/2)-dependent phosphorylation of syanpsin-1 (58). Additionally, activity of
the receptor has been linked to the phosphorylation of cyclic adenosine
monophosphate response element binding protein through protein kinase A-dependent
activation of ERK1/2 (65, 66), which may result in the expression of genes that are
important for synaptic plasticity (42, 67). The α7 nAChR may also play a role in
neuroprotection through the phosphatidyl-inositol 3-kinase-dependent signalling
pathway (68, 69).

1.8 Regulation of the α7 nAChR
A number of factors that regulate function of the α7 nAChR have been identified.
Through primary amino acid sequence analysis, several amino acid residues within the
large intracellular loop of the α7 nAChR appear to be important for cell surface
expression in Xenopus laevis (70). These residues may act in a manner similar to the
endoplasmic reticulum (ER) retention motif identified on the α1 nAChR subunit, which is
conserved among heteromeric-receptor forming nAChR subunits (71). Post-
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translational modification of the α7 nAChR in the form of palmitoylation appears to be
required for the assembly of α7 nAChR subunits into functional receptors in PC12 cells
(72). It is apparent that host-cell specific subcellular proteins are required for functional
expression of α7 nAChR, as α7 nAChR subunits heterologously expressed in HEK 293
cells do not form functional αBTX-binding channels unless they are co-expressed with
the chaperone protein RIC3 (73 - 75), the product of the Caenorhabditis elegans gene,
resistant to inhibitors of cholinesterase (ric-3), an ER protein that co-ordinates efficient
assembly of α7 nAChR subunits into receptor pentamers (76). Receptor activity can be
regulated by Src-family tyrosine kinases directly through phosphorylation of tyrosine
residues on the large intracellular loop of the α7 nAChR subunit (77) and indirectly in a
manner that does not involve phosphorylation of the receptor, but is mediated by Nethylmaleimide-sensitive factor attachment protein receptors (SNAREs) (78). SNAREs
are also involved in the activity dependent recycling of cell surface α7 nAChR in
response to nicotine stimulation (79). Additionally, somatodendritic localization of
α7 nAChR on hippocampal neurons is regulated by a tyrosine motif in the large
intracellular loop of the subunit (63). Although several of these studies focused on
factors that are involved in the assembly and insertion of α7 nAChR into the plasma
membrane, few have described mechanisms involved in its removal from the cell
surface and receptor down-regulation. Chapter 3 of this thesis demonstrates that
binding of the competitive antagonist αBTX leads to receptor internalization through a
unique endocytic mechanism and trafficking of the receptor to a degradative
compartment in the cell.

1.9 The α7 nAChR in Alzheimer’s Disease Pathology
Positron emission tomography studies employing 11C-nicotine to measure nAChR levels
in the brains of AD subjects have demonstrated a global reduction in nAChRs in the
brain that correlate with cognitive impairment (80). However, more recent
investigations with the α7 nAChR-selective ligand [3H]-methyllycaconitine (MLA) suggest
that the α7 nAChR may not change during the progression of cognitive decline (81).
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With the development of transgenic mouse models that express proteins linked to
familial or early-onset AD, investigators have determined that α7 nAChR in
hippocampus may be up-regulated in response to increased amyloid β peptide
production (82). Critically, knockout of the α7 nAChR gene from an AD mouse model
protects against the synaptic dysfunction and learning and memory deficits associated
with expression of the AD-related transgene (83)

1.10 Amyloid β Peptides
The proteolysis of the integral membrane protein amyloid β precursor protein (APP),
resulting in the generation of amyloid β (Aβ) peptides, is hypothesized to be an initiating
event in AD pathology (84). Aβ peptides are generated from the sequential cleavage of
APP, first by β-secretase activity of the β-site APP-cleaving enzyme (85), resulting in
shedding of the APP ectodomain, then by intra-membrane cleavage of the remaining
transmembrane fragment of APP by the γ-secretase complex, resulting in the secretion
of Aβ peptide and the release of the APP intracellular domain (86, 87). The γ-secretase
complex is composed of four proteins, presenilin-1 (PS1) or PS2, nicastrin, APH1 and
PEN2 (85, 88 - 90). β- and γ-secretase cleavage of APP can generate multiple Aβ peptide
fragments, with the most abundant being 40 (Aβ40) or 42 (Aβ42) amino acids in length,
depending on the site of cleavage (84). Each contains a small portion of the APP
transmembrane domain (84). Mutations in APP, PS1 and PS2 are linked to early onset
familial AD, resulting from an increased ratio of Aβ42/Aβ40 generation (84). Aβ42
contains two additional hydrophobic amino acid residues, increasing its potential for
aggregation into soluble oligomeric forms which can bind receptors and interfere with
synaptic transmission, or form insoluble fibrillar aggregates found at the core of amyloid
plaques in the end stages of AD (84). Measures of the levels of soluble Aβ in the brain
are a better correlate with the presence and degree of cognitive deficits than the
burden of Aβ plaques, suggesting soluble Aβ is a causative factor in AD pathology (91 94).
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1.11 Aβ Peptides and the α7 nAChR
Initial studies that investigated the interaction between Aβ and α7 nAChR were based
on observations that α7 nAChR expression correlated with brain areas that exhibited Aβ
plaques, particularly the hippocampus and cerebral cortex (95). The α7 nAChR was
found to co-immunoprecipitate with Aβ42 from human AD brain tissue and localize to
Aβ plaques in the hippocampus (95). Subsequent studies determined that Aβ42 binds
with high affinity to the α7 nAChR (96) and that cell surface expression of α7 nAChR can
facilitate intracellular accumulation of the peptide (97). Electrophysiology experiments
determined Aβ42 could either activate α7 nAChR responses in heterologous expression
systems (98) or inhibit ACh-evoked receptor responses in the same systems (99, 100) or
from native α7 nAChR in hippocampus (101). These observations are not without
controversy, as it is apparent that Aβ42 can activate Ca2+ signalling independent of
receptor binding (102) and that Aβ42 may interact directly with plasma membrane lipids
(103). An important caveat that may explain these differences is that the Aβ peptides
used in these experiments have largely been uncharacterized in terms of the different
structural forms present or the state of aggregation of the peptide. Given the
propensity for Aβ42 to aggregate in solution, it is difficult to make comparisons between
studies that have not characterized the aggregation state of the peptide because
different aggregates may yield different physiological outcomes. In Chapter 2 of this
thesis, I examined the effects of different structural forms of Aβ42 peptides upon
extracellular signal-regulated kinase mitogen-activated protein kinase (ERK/MAPK)
signalling through the α7 nAChR and identify oligomeric aggregates as the biologically
relevant form.
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1.12 Objectives and Hypotheses Tested in this Thesis

My research interests lie in characterizing the structural forms of Aβ42 peptide capable
of activating α7 nAChR-dependent intracellular signalling pathways. There is evidence
Aβ42 peptide binds the α7 nAChR to activate the receptor ion channel (95) and
receptor-dependent signalling pathways (82). However, the state of aggregation of
Aβ42 peptide in these experiments has not been fully characterized, and the structural
forms of the peptide capable of activating the α7 nAChR have yet to be determined. I
am also interested in investigating subcellular mechanisms that may be involved in
regulating cell surface levels of the α7 nAChR. A number of cell surface receptors
undergo regulated endocytosis in response to ligand binding as a means of modulating
receptor-dependent signalling. I would like to determine if ligand binding induces
internalization of the α7 nAChR and elucidate the subcellular mechanisms involved in
this process.

1.12.1

Specific Aims:

1) To identify the structural form of Aβ42 peptide aggregates that signal through the
α7 nAChR and characterize their effects with dose and time.
2) To identify factors that affect cell surface expression of the α7 nAChR and elucidate
the subcellular mechanisms involved.
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1.12.2

Study One: Oligomeric Aggregates of Amyloid β Peptide 1-42
Activate ERK/MAPK in SH-SY5Y Cells via the α7 Nicotinic Receptor

Rationale: Previous studies have shown that Aβ42 peptide activates the ERK/MAPK
intracellular signalling pathway through the α7 nAChR (82, 104). However, Aβ42
peptide readily aggregates in solution to take on different structural forms with
different biological consequences and the structural form of the peptide in these studies
was not characterized. Thus, the aim of this study was to determine the structural form
of Aβ42 peptide aggregates capable of activating ERK/MAPK signalling through the
α7 nAChR.
Hypothesis: Aβ42-dependent ERK/MAPK signalling through the α7 nAChR is
independent of the structural form or aggregation state of the peptide.
Outcome: Using atomic force microscopy, I characterized Aβ42 peptide that had been
pre-incubated under different solution conditions to yield either oligomeric or fibrillar
aggregates. When these were added to human neuroblastoma cells in culture and
changes in ERK1/2 phosphorylation were measured by immunoblotting, oligomeric
aggregates of Aβ42 acutely increased phosphorylation of ERK1/2 in a concentration- and
time-dependent manner. Fibrillar aggregates of Aβ42 or Aβ42 that had not been preincubated to induce aggregate formation did not significantly change the level ERK1/2
phosphorylation. Importantly, MLA, a competitive antagonist selective for the
α7 nAChR, inhibited oligomeric Aβ42-induced ERK1/2 phosphorylation. Thus, oligomeric
aggregates of Aβ42 are the structural form of the peptide that activates ERK/MAPK
through the α7 nAChR.
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1.12.3

Study Two: The α7 Nicotinic Receptor is Internalized via a
Clathrin-Independent, Flotillin- or Caveolin-Associated Endocytic
Pathway

Rationale: Some ionotropic neurotransmitter receptors undergo regulated clathrindependent endocytosis in response to ligand binding, a process that maintains the
integrity of neurotransmission (105, 106). Primary amino acid sequence analysis of the
large intracellular loop of the α7 nAChR subunit revealed two clathrin adaptor-protein
binding motifs that could regulate trafficking of the receptor from the cell surface. The
aim of this study was to determine if the α7 nAChR undergoes endocytosis in response
to ligand binding and to determine the subcellular mechanisms involved.
Hypothesis: Cell surface expression of the α7 nAChR is not regulated by clathrin and
dynamin and is independent of adaptor protein binding motifs within the large
intracellular loop of the receptor subunit.
Outcome: Confocal microscopy of cells fixed following pulse-chase with fluorochromelabelled αBTX revealed binding αBTX caused internalization of the α7 nAChR. Following
internalization, α7 nAChR-αBTX complexes trafficked to early and late endosomes and
lysosomes, subcellular membrane compartments identified by antibody labelling of
endogenous and heterologous expression of fluorescent protein-tagged compartmental
markers. Null mutation of clathrin adaptor-protein binding motifs within the large
intracellular loop of the α7 nAChR subunit did not prevent αBTX-induced receptor
internalization. Over-expression of dominant negative proteins that block clathrindependent endocytosis determined internalization did not occur through a clathrindependent mechanism. Inhibition of actin cytoskeleton polymerization, and overexpression of dominant negative proteins that block actin dynamics, determined
internalization did not occur through common clathrin-independent mechanisms.
Rather, internalized α7 nAChR-αBTX complexes localized with fluorescent proteintagged flotillin 1 and caveolin 1α, markers for specialized plasma membrane regions
associated with clathrin-independent endocytosis. Thus, I demonstrate αBTX binding to
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the α7 nAChR causes internalization through a clathrin-independent flotillin 1- or
caveolin 1α-associated pathway, and trafficking through early and late endosomes to
the lysosomal compartment.
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2.1 Summary
The production and aggregation of amyloid β peptides is linked to the development and
progression of Alzheimer’s disease. It is apparent that the various structural forms of Aβ
can affect cell signalling pathways and the activity of neurons differently. In this study,
we investigated the effects of oligomeric and fibrillar aggregates of Aβ42 and nonaggregated peptide upon activation of the ERK/MAPK signalling pathway. In SH-SY5Y
cells, acute exposure to oligomeric Aβ42 led to phosphorylation of ERK1/2 at
concentrations as low as 1 nM and up to 100 nM. These changes were detected as early
as 5 min following exposure to 100 nM oligomeric Aβ42, reaching a maximum level after
10 min. Phosphorylation of ERK1/2 subsequently declined to and remained at basal
levels after 30 min, for up to 2 h of exposure. Fibrillar aggregates of Aβ42 did not
significantly induce phosphorylation of ERK1/2 and non-aggregated Aβ42 did not
activate the pathway. The effects of oligomeric Aβ42 to increase ERK1/2
phosphorylation above basal levels were inhibited by MLA, a selective antagonist of the
α7nAChR. U0126, an inhibitor of MEK1/2, the upstream activator of ERK1/2, completely
blocked induction of ERK1/2 phosphorylation. Oligomeric aggregates of Aβ42 were the
principal structural form of the peptide that activated ERK/MAPK in SH-SY5Y cells and
these effects were mediated by the α7 nAChR.

32

2.2 Introduction
Alzheimer’s disease is a common form of progressive neurodegeneration that manifests
itself as impaired learning and memory and disordered cognitive function (1). Although
AD can occur sporadically with a prevalence that increases with age, it has also been
linked genetically to the overproduction and aggregation of Aβ peptides (1). Aβ
peptides are derived from the proteolytic degradation of a type I integral membrane
protein, amyloid precursor protein (APP) (2). Cleavage of APP by β- and γ-secretase
activity results in the production of peptides that are predominantly either 40 or 42
amino acids in length (Aβ40 or Aβ42) (2). Familial AD-causing mutations in APP or the γsecretase protein presenilin result in either the increased production of Aβ peptides
and/or an increase in the relative amount of Aβ42 versus Aβ40 produced (2). Aβ42
contains two additional hydrophobic amino acid residues than Aβ40 and aggregates
more readily in solution (3, 4). Fibrillar aggregates of Aβ42 are found at the core of
amyloid plaques in the brain and Aβ42 accounts for the majority of Aβ found within
these plaques (5). However, the appearance, number, and distribution of plaques does
not correlate well with measures of clinical dementia; rather it is the levels of soluble Aβ
peptides that correlate more strongly with the loss of synaptic terminals and dementia
in AD (6 - 9). These small soluble aggregates of Aβ peptides are detectable in extracts
from AD brain, the media of cell cultures and in synthetic preparations of Aβ peptides (9
- 14). These oligomeric aggregates of Aβ can inhibit long-term potentiation (LTP; a
classical model of synaptic plasticity and learning and memory) in in vitro and in in vivo
models at nanomolar concentrations (15). Recent evidence from studies using a
genetically modified mouse model of AD revealed that senile plaques can serve as a
reservoir for the release of oligomeric Aβ and that this can be toxic to synapses at some
distance from the plaque (16).
LTP is dependent upon intracellular signalling, particularly activation of the ERK/MAPK
signal transduction pathway (17 - 19). The α7 nAChR plays a role in the formation of LTP
in the hippocampus and this can involve signalling through ERK/MAPK (20 - 22). An
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interaction between Aβ42 and the α7 nAChR has been implicated in the activation of
ERK/MAPK in the hippocampus where disjunctive Aβ42-α7 nAChR-ERK/MAPK signalling
may disrupt ERK/MAPK signalling important for the formation of LTP (23, 24).
The findings of some, but not all studies suggest that Aβ42 binds the α7 nAChR with
high affinity and can alter gating of the receptor, either by activating the receptor as an
agonist or antagonizing receptor activity (25 - 31). The effects of Aβ42 binding to the
α7 nAChR and the ability of the peptide to activate receptor-linked intracellular
signalling pathways are likely affected by the state of aggregation and structural form of
the peptide. Previous studies have addressed the possible role of Aβ42 in activation of
downstream signalling pathways engaged by the α7 nAChR, but those studies did not
involve documentation of the aggregation state or structural forms of Aβ42 peptides
responsible for mediating these effects (24).
In the present study, activation of the ERK/MAPK signalling pathway by wellcharacterized oligomeric and fibrillar aggregates of Aβ42 and non-aggregated Aβ42 was
compared in the SH-SY5Y human neuroblastoma cell line. Synthetic Aβ42 peptides were
treated to remove any pre-existing structural forms and subsequently incubated under
conditions that promoted the formation of either oligomeric or fibrillar aggregates.
Alternatively, the peptides were not incubated prior to their application to cultured
neuronal cells to prevent the formation of these aggregates and to retain the peptides
in monomeric form. The preparations were applied to SH-SY5Y cells in vitro and the
acute effects upon phosphorylation of ERK1/2 were monitored to obtain a doseresponse and time-course for oligomeric, fibrillar or non-aggregated forms of Aβ42. The
involvement of the α7 nAChR was assessed with the use of a competitive antagonist
selective for the receptor, MLA.
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2.3 Methods
2.3.1

Materials

SH-SY5Y cells were purchased from American Type Tissue Culture (Manassas, VA).
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and Ham’s F-12
nutrient mixture (phenol red-free) were obtained from Invitrogen (Burlington, ON).
Aβ42 peptides were from Bachem (Torrance, CA) and California Peptide Research (Napa,
CA); no differences were found in experimental measures made between the two
peptide sources. Nerve growth factor 2.5S (NGF) was from Harlan Bioproducts
(Indianapolis, IN). U0126 was from Calbiochem (Gibbstown, NJ). MLA, 1,1,1,3,3,3hexafluoro-2-propanol (HFIP), dimethyl sulfoxide (DMSO) and bovine serum albumin fraction V (BSA) were from Sigma-Aldrich (Oakville, ON). Polyclonal antibodies against
dually phosphorylated ERK1/2 and monoclonal and polyclonal antibodies against ERK1/2
were from Cell Signaling Technology (Danvers, MA). Polyclonal antibody against the Cterminus of actin was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Horseradish
peroxidase (HRP)-conjugated goat anti-rabbit antibody was from Jackson ImmunoResearch Laboratories (West Grove, PA). HRP-conjugated sheep anti-mouse antibody,
ECL western blotting detection reagent and Hybond-C Extra nitrocellulose membrane
were from GE Healthcare (Baie d’Urfé, QC). X-OMAT LS film was from Eastman Kodak
(Toronto, ON).

2.3.2

Aβ42 Preparation and Atomic Force Microscopy

Oligomeric and fibrillar forms of Aβ42 were prepared as described previously (14, 32).
The preparation of Aβ42 peptides and treatment of cells in culture is illustrated (Figure
2.1). Briefly, lyophilized Aβ42 peptides were dissolved in HFIP and aliquoted into
polypropylene micro-centrifuge tubes. HFIP was removed by evaporation and the
resulting Aβ42 peptide films were stored at - 80 °C. Prior to use, these peptide films
were reconstituted to give an Aβ42 stock solution at a concentration of 1 mM in DMSO,
sonicated for 10 min, then subsequently diluted to 100 μM with ice-cold Ham’s F-12
(phenol red-free) and incubated for 24 h at 4 °C to facilitate the formation of Aβ42
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Figure 2.1 Preparation of Aβ42 Peptides and Cell Culture Treatments.
(i) Chemically synthesized Aβ42 peptide was obtained from a commercial source as a lyophilized
product. (ii) To ensure that the starting material was in a homogenous non-aggregated
monomeric state, the lyophilized peptide was dissolved in HFIP and aliquoted into microcentrifuge tubes. (iii) HFIP was removed by evaporation in a vacuum centrifuge to yield a
peptide film. (iv) Peptide films were reconstituted in DMSO to a concentration of 1 mM and
sonicated for 10 min immediately prior to (v) dilution to 100 μM in ice-cold Ham’s F-12, 10 mM
HCl, or PBS, pH 7.4. DMSO solutions diluted in Ham’s F-12 were incubated for 24 h at 4 °C to
form oligomeric aggregates and solutions diluted in 10 mM HCl were incubated for 24 h at 37 °C
to form fibrillar aggregates. Solutions diluted in PBS were not incubated to prevent the
formation of aggregates and yield a non-aggregated form of Aβ42. (vi) The resulting stock
solutions were serially diluted on ice prior to being added to cells in culture.
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oligomers. Alternatively, the DMSO stock solution was diluted to 100 μM with 10 mM
HCl and incubated for 24 h at 37 °C to facilitate the formation of Aβ42 fibrils. For nonaggregated Aβ42, DMSO stock solutions were diluted to 100 μM with ice-cold
phosphate-buffered saline (PBS) (138 mM NaCl, 2.7 mM KCl), pH 7.4. Peptide
preparations were either stored at - 80 °C or used immediately for treatment of cells or
atomic force microscopy (AFM). Non-aggregated Aβ42 preparations in PBS were used
immediately. Aβ42 aggregates were characterized by TappingMode™ AFM using a
Multimode SPM with a NanoScope™ IIIa controller and J-series scanner (Digital
Instruments) (Figure 2.2). AFM probes were Tap 300 silicon cantilevers with 40 N/m
spring constants and 300 kHz resonant frequencies (Nanodevices). Aβ42 solutions at
10 μM were spotted onto freshly-cleaved mica, incubated for 1 min, then rinsed twice
with high performance liquid chromatography (HPLC)-grade H2O and blown dry with
compressed air. Images of bare mica were captured from freshly-cleaved mica spotted
with an equivalent volume of HPLC-grade H2O and blown dry. Samples were imaged at
scan rates from 0.5 to 5 Hz with drive amplitude and contact force kept to a minimum.
Section analysis of images was performed to measure the height of Aβ42 aggregates on
the surface of mica substrate (Figure 2.2 D and E). Aggregate heights were measured
individually in images captured from three to four independent preparations of Aβ42 for
each form of the peptide; oligomeric, fibrillar, or non-aggregated. The periodicity of
fibrils was determined by measuring the distance between peaks of subunits.

2.3.3

Cell Model

The SH-SY5Y cell line is a human cell line sub-cloned from the SK-N-SH cell line (33)
originally isolated from a human metastatic neuroblastoma (34). SH-SY5Y cells
endogenously express α7 nAChR (35, 36) and they have been successfully employed in
several studies to investigate subcellular signalling the α7 nAChR (37 - 41). A signalling
pathway for activation of ERK/MAPK through α7 nAChR has been characterized in SHSY5Y cells (42), making them a candidate model for investigating ERK/MAPK activation
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Figure 2.2 Atomic Force Microscopy and Image Analysis.
(A) AFM is a form of scanning probe microscopy that generates very high resolution topographic
images by monitoring the interaction of a physical probe with a sample surface. In
TappingMode™ AFM, a cantilever and tip integrated on a single silicon crystal is oscillated at or
near its resonance frequency at a set amplitude and lightly taps across a sample surface during
scanning. Laser light reflected off the back of the cantilever is detected by two closely spaced
photodiodes. Displacement of the cantilever as it scans across the sample surface alters the
amount of light reflected into each photodiode. The amount of light received by each
photodiode is proportional to the deflection of the cantilever. A feedback loop maintains the
constant oscillation amplitude by vertically moving the scanner in the (z) at each (x,y) data point.
The distance the scanner moves vertically at each (x,y) data point is recorded to create a
topographic image of the sample surface. Adapted from (43). (B) Data sets can be presented as
an image in two-dimensions with a vertical colour scale, or (C) visualized in three-dimensions as
a perspective. (D) Section analysis performed on images in which cross-sections (white line)
through aggregates were examined to measure the height of each aggregate individually. (E)
Profile of cross-section from D, measurement indicated by red arrowheads is a height of 2.9 nm.
B, C, D, and E are from the same data set.

39

40

as an endpoint to discriminate between the signalling capability of different structural
forms of Aβ42 peptide in relation to the α7 nAChR.

2.3.4

Cell Culture and Treatments

SH-SY5Y cells were maintained in 75 cm2 flasks using DMEM supplemented with 10%
FBS and 0.05 mg/ml gentamycin at 37 °C in humidified air with 5% CO2. Cells were
plated onto 35 mm dishes two days prior to experimentation, with media changed to
serum-free media containing 0.1% BSA 24 h prior to experiments. Treatment groups
included 50 ng/mL NGF for 5 min; 5 min incubation with 0.01, 0.1, 1, 10, or 100 nM
oligomeric, fibrillar or non-aggregated Aβ42, or 100 nM oligomeric, fibrillar or nonaggregated Aβ42 for 2, 5, 10, 30, 60 or 120 min. The inhibitors MLA (10 nM) or U0126
(50 mM) were added 30 min prior to the addition of 100 nM oligomeric Aβ42. Stock
solutions of MLA at 10 mM in distilled H2O were stored at - 80 °C and activity was tested
in Ca2+ fluorimetry experiments in which 10 µM MLA, diluted from stock, blocked 1 mM
nicotine induced increases in intracellular Ca2+ in SH-SY5Y cells loaded with the Ca2+sensitive dye fura-2. The concentration of Aβ42, whether oligomeric, fibrillar, or nonaggregated, was estimated based on dilution from that of the starting material,
originally reconstituted from peptide films to 1 mM in DMSO.

2.3.5

Immunoblotting

At the end of the specified treatment periods, cells were washed twice with ice-cold
PBS, scraped into lysis buffer comprised of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1%
Triton X-100, 1 mM AEBSF, 10 mM NaF, 500 mM NaVO4, 10 mg/ml leupeptin, 25 mg/ml
aprotinin and 10 mg/ml pepstatin-A and incubated on ice for 30 min. The protein
concentration of each lysate was determined by the method of Bradford (44). Equal
amounts of protein (50 mg per sample) were resolved on 10% polyacrylamide gels by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to the
method of Laemmli (45). To limit the overexposure of immunoblots caused by the
intensity of NGF-induced bands, 50% less protein (25 mg per sample) from cells treated
with NGF was loaded onto each SDS-PAGE gel. Proteins were transferred to
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nitrocellulose membranes and immunoblotted with phosphorylation-specific (antiphosphorylated p44/42 ERK1/2; 1:1000) or phosphorylation state independent (antip44/42 ERK1/2; 1:1000) anti-ERK1/2 antibodies. Immunoblotting with anti-actin
antibody (1:5000) was used to demonstrate equal loading and transfer of SDS-PAGE
gels. Anti-rabbit or anti-mouse IgG HRP-conjugated secondary antibodies (1:20,000 or
1:5000, respectively), followed by ECL reagent were used to detect immunoreactive
protein bands. Immunoblots were quantified by densitometry with Quantity One
software, version 4.6 (Bio-Rad, Mississauga, ON). The density of phosphorylated ERK1
and phosphorylated ERK2 proteins, resolving as two separate immunoreactive bands,
were quantified as a single value.

2.3.6

Statistical Analysis

Results from the densitometric analysis of immunoblots are presented as a percentage
of control responses and the data are given as mean ± SEM from three or more separate
experiments where indicated. Statistical significance was determined by one-way
analysis of variance (ANOVA), followed by post hoc Dunnett analysis. A value of p < 0.05
was considered to be statistically significant.

2.4 Results
2.4.1

Generation of Oligomeric and Fibrillar Aggregates of Aβ42

Aβ42 in aqueous solution spontaneously assembles into aggregates of various sizes and
conformations that have been determined to have unique biological properties (46). To
differentiate between the effects of these different forms of Aβ42 in our studies, it was
important that we produce solutions of Aβ42 that could be documented in terms of the
structural forms of peptides present and demonstrated to be enriched in specific Aβ42
conformations. We chose to follow a method previously established to produce specific
structural forms of Aβ42 (14, 32). We employed AFM to evaluate the aggregation state
of our peptide preparations and were able to consistently produce small oligomeric or
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fibrillar aggregates of Aβ42 that were distinct from non-aggregated Aβ42 and the
surface of bare mica (Figure 2.3).
Oligomeric preparations of Aβ42 contained small round globular structures with an
average height of 3.1 ± 0.7 nm (n = 100), ranging in size from 1.3 to 4.4 nm. Oligomeric
aggregates 3.0 - 3.8 nm in height were in the greatest frequency and there appeared to
be a second smaller population circa 2 nm in height (Figure 2.4). Fibrillar preparations
of Aβ42 contained elongated fibrils that extended in length from tens of nanometres to
micrometres. These fibrils appeared to be comprised of oligomeric-like subunits with an
average height of 2.5 ± 0.3 nm (n = 50) that exhibited a distinct periodicity of 36 ± 3 nm
(n = 20). Some small round globular aggregates were also present in fibrillar
preparations, and these structures had an average height of 1.9 ± 0.5 nm (n = 50),
ranging from 1.1 to 3.2 nm, with 80% of the population 1.4 - 2.6 nm in height. We
observed that the majority of the peptide material in fibrillar preparations of Aβ42 was
confined to elongated fibrils. Non-aggregated preparations of Aβ42 contained relatively
small infrequent globular structures with an average height of 0.5 ± 0.4 nm (n = 50),
ranging in size from 0.2 to 2.0 nm, with 90% of the population 0.2 - 1.0 nm in height.
Thus, the forms of Aβ42 used in our experiments were either oligomeric aggregates,
predominantly fibrillar aggregates, or a non-aggregated form of the peptide containing
smaller and less abundant aggregate structures.

2.4.2

ERK/MAPK Phosphorylation Induced by Oligomeric Aggregates of
Aβ42

Acute exposure of SH-SY5Y cells for 5 min to oligomeric aggregates of Aβ42 induced
ERK1/2 phosphorylation that was greater than that observed in cells treated with either
fibrillar or non-aggregated Aβ42 (Figure 2.5). However, the oligomeric Aβ42-induced
ERK1/2 phosphorylation was less than that mediated by NGF (Figure 2.5 A). The levels
of total ERK1/2 and actin were unaffected by treatment of cells with Aβ42. Oligomeric
Aβ42 induced ERK1/2 phosphorylation in a dose-dependent manner when cells were
exposed to concentrations between 0.01 and 100 nM, with the maximum effect
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Figure 2.3 Atomic force microscopy of oligomeric, fibrillar and non-aggregated
preparations of Aβ42.
Lyophilized Aβ42 was dissolved in HFIP, dried, re-suspended in DMSO, sonicated, and then
incubated for 24 h following dilution in either fresh cell culture medium at 4 °C to yield
Oligomeric or 10 mM HCl at 37 °C to yield Fibrillar aggregates. For Non-aggregated Aβ42,
DMSO solutions were diluted in ice-cold PBS, pH 7.4. HPLC-grade H2O was used in the place of
Aβ42-containing preparations to image the surface of bare mica. Aβ42-containing samples were
mounted on freshly-cleaved mica at a concentration of 10 μM for AFM. Images are
representative 5 μm × 5 μm x-y (Oligomeric and Fibrillar) or 2 μm × 2 μm x-y (Non-aggregated
and HPLC-grade H2O), 10 nm z-range taken from AFM; insets are 250 nm × 250 nm x-y, 10 nm zrange. Images are representative of samples taken from independent preparations (oligomeric
Aβ42, n = 4; fibrillar Aβ42, n = 3; non-aggregated Aβ42, n = 3; HPLC-grade H2O, n = 3). Bar, 1 μm.

44

45

Figure 2.4 Distribution of aggregate heights within oligomeric preparations of Aβ42.
Section analysis was performed on images captured by AFM from four independent oligomeric
preparations of Aβ42 peptide. Cross-sections through aggregates were examined individually to
measure their heights, 25 aggregates were examined per image. The distribution of aggregate
heights within oligomeric preparations of Aβ42 are represented as a percentage of the total
population (n = 100).

achieved at a concentration of 100 nM. When SH-SY5Y cells were treated with fibrillar
Aβ42 in the same concentration range as oligomeric Aβ42, ERK1/2 phosphorylation was
increased slightly above basal levels, but this did not increase at higher concentrations
as was observed for the oligomeric form of the peptide. Non-aggregated Aβ42 did not
activate ERK1/2 under these conditions. At concentrations of 0.1, 1 and 100 nM,
oligomeric Aβ42 significantly activated ERK1/2 when compared to the basal level of
ERK1/2 phosphorylation in untreated SH-SY5Y cells (Figure 2.5 B). In these experiments,
NGF treatment of cells was used as a well-characterized positive control for ERK/MAPK
activation. NGF induced ERK1/2 phosphorylation to a level at least twice that observed
for oligomeric Aβ42.
Oligomeric aggregates of Aβ42, at a concentration of 100 nM, induced ERK1/2
phosphorylation in a time-dependent manner (Figure 2.6). When SH-SY5Y cells were
treated with oligomeric Aβ42, the level of ERK1/2 phosphorylation increased from 2 to
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Figure 2.5 Phosphorylation of ERK1/2 induced by Aβ42 is dependent upon the
concentration and structural form of the peptide.
(A) SH-SY5Y cells were treated with oligomeric or fibrillar aggregates of Aβ42 or non-aggregated
Aβ42 at concentrations of 0.01, 0.1, 1, 10, and 100 nM, or 50 ng/mL NGF for 5 min. Cells were
lysed and proteins were resolved by SDS-PAGE and transferred to nitrocellulose membrane for
immunoblotting for phosphorylated ERK1/2, total ERK1/2 or actin. Representative immunoblots
are shown. (B) Immunoblots were analyzed by densitometry, the density of phosphorylated
ERK1 and phosphorylated ERK2 bands were quantified together as a single value. Values were
expressed as a percentage of the basal level of phosphorylated ERK1/2 measured in untreated
control cells. Oligomeric Aβ42 significantly induced phosphorylation of ERK1/2 at
concentrations of 1, 10, and 100 nM when compared to control cells (*p < 0.05), as determined
by one-way ANOVA and post hoc Dunnett analysis. Fibrillar or non-aggregated Aβ42 did not
significantly affect phosphorylation of ERK1/2. Data are mean ± SEM (bars) values (oligomeric
Aβ42, n = 6; fibrillar Aβ42, n = 6; non-aggregated Aβ42, n = 4).
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Figure 2.6 Phosphorylation of ERK1/2 induced by Aβ42 is dependent upon the
exposure time and structural form of the peptide.
(A) SH-SY5Y cells were exposed to oligomeric or fibrillar aggregates of Aβ42 or non-aggregated
Aβ42 at a concentration of 100 nM for 2, 5, 10, 30, 60, or 120 min. Cells were lysed and proteins
were resolved by SDS-PAGE and transferred to nitrocellulose membrane for immunoblotting for
phosphorylated ERK1/2, total ERK1/2 or actin. Representative immunoblots are shown. (B)
Immunoblots were analyzed by densitometry, the density of phosphorylated ERK1 and
phosphorylated ERK2 bands were quantified together as a single value. Values were expressed
as a percentage of the basal level of phosphorylated ERK1/2 measured in untreated control
cells. 100 nM oligomeric Aβ42 significantly induced phosphorylation of ERK1/2 after 5 min (*p <
0.05) and maximally affected ERK1/2 phosphorylation after 10 min of exposure (**p < 0.01).
Fibrillar or non-aggregated Aβ42 did not significantly affect phosphorylation of ERK1/2 with
time. Significance was determined by one-way ANOVA and post hoc Dunnett analysis, data are
mean ± SEM (bars) values (oligomeric Aβ42, n = 6; fibrillar Aβ42, n = 3; non-aggregated Aβ42, n
= 4).
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5 min and reached a maximum after 10 min of exposure, before returning to basal levels
at 30 to 120 min after the initiation of treatment (Figure 2.6 A). Although 100 nM
fibrillar Aβ42 appeared to induce slight ERK1/2 phosphorylation in a time-dependent
manner similar to oligomeric Aβ42, the level of ERK1/2 phosphorylation was much less
than that caused by oligomeric Aβ42 and only slightly above the basal level of ERK1/2
phosphorylation in untreated SH-SY5Y cells. At the same concentration, non-aggregated
Aβ42 did not alter ERK1/2 phosphorylation over the time frame examined. When these
effects were quantified, 100 nM oligomeric Aβ42 significantly induced ERK1/2 activation
in SH-SY5Y cells after 5 and 10 min of exposure (Figure 2.6 B).

2.4.3

Effect of α7 nAChR Antagonist Methyllycaconitine on ERK/MAPK
Phosphorylation Induced by Oligomeric Aβ42

To investigate whether the α7 nAChR was involved in oligomeric Aβ42-induced ERK1/2
phosphorylation in SH-SY5Y cells, we examined the effect of the α7 nAChR-selective
competitive antagonist, MLA (Figure 2.7). In the absence of MLA, ERK1/2
phosphorylation induced by 100 nM oligomeric Aβ42 was elevated approximately twofold when compared to that of the basal level in untreated SH-SY5Y cells (Figure 2.7 B).
Pre-incubation of cells with 10 nM MLA prior to the addition of oligomeric Aβ42
attenuated the increase in ERK1/2 phosphorylation to near basal levels (Figure 2.7).
When MLA was added to cells alone, it did not affect basal ERK1/2 phosphorylation
(Figure 2.7). This suggests that oligomeric Aβ42 may be acting, at least in part, through
the α7 nAChR to induce ERK1/2 phosphorylation in SH-SY5Y cells. Next, we determined
the effect of inhibition of MAPK kinase 1 and 2 (MEK1/2) upon oligomeric Aβ42-induced
ERK1/2 phosphorylation. MEK1/2 resides directly upstream of ERK1/2 in the ERK/MAPK
cascade (47) and is required for the activation of this pathway in SH-SY5Y cells by
nicotine (42). In the presence of the MEK1/2 inhibitor U0126, ERK1/2 phosphorylation
was completely abolished in both untreated cells and cells that were treated with
oligomeric Aβ42 (Figure 2.7 A).
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Figure 2.7 Oligomeric Aβ42-induced ERK1/2 phosphorylation is dependent upon the
α7 nAChR and the upstream MAPK kinase, MEK1/2.
SH-SY5Y cells were exposed to 100 nM oligomeric Aβ42 alone, or pre-incubated with 10 nM
MLA or 50 mM U0126 for 30 min prior to the addition of 100 nM oligomeric Aβ42. (A) Cells
were lysed and proteins were resolved by SDS-PAGE and transferred to nitrocellulose
membrane for immunoblotting for phosphorylated ERK1/2, total ERK1/2 or actin as outlined in
the Methods. U0126, an inhibitor of MEK1/2, completely abolished ERK1/2 phosphorylation
compared to untreated cells and cells that were exposed to oligomeric Aβ42. MLA, a specific
antagonist of the α7 nAChR, did not alter ERK1/2 phosphorylation on its own, but prevented the
phosphorylation of ERK1/2 induced by oligomeric Aβ42. Representative immunoblots are
shown from six independent experiments. (B) Immunoblots were analyzed by densitometry,
the density of phosphorylated ERK1 and phosphorylated ERK2 bands were quantified together
as a single value. Values were expressed as a percentage of the basal level of phosphorylated
ERK1/2 measured in untreated control cells. Data are mean ± SEM values (n = 6).
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2.5 Discussion
In the present study, we demonstrate that oligomeric aggregates of Aβ42 are the
principal structural form of Aβ42 peptides responsible for activation of the ERK/MAPK
signalling pathway. Oligomeric aggregates of Aβ42 activate ERK/MAPK in a
concentration and time-dependent manner in SH-SY5Y cells. Phosphorylation of ERK1/2
induced by oligomeric Aβ42 is blocked by MLA, a competitive antagonist selective for
the α7 nAChR, and occurs through a mechanism that requires MEK1/2 as an upstream
mediator of ERK1/2 activity.
To differentiate between the biological effects of fibrillar and soluble oligomeric forms
of Aβ42, we followed a protocol established by Stine and colleagues that defined
conditions for the aggregation of Aβ42 into either oligomeric or fibrillar structures (14,
32). In the absence of incubation under these conditions, non-aggregated Aβ42, that
lacked the structural complexity of oligomeric or fibrillar preparations, was obtained.
The oligomeric aggregates that we generated were in the 2 - 4 nm height range of
oligomers (mean 3.1 ± 0.7 nm) reported by Stine et al., and the images that we obtained
by AFM support their findings that the conditions they describe yield predominantly
either oligomeric or fibrillar aggregates of Aβ42 (32). These oligomeric aggregates are
structurally similar in size and appearance to the Aβ-derived diffusible ligands generated
by others, analogues of which have been detected in the cerebrospinal fluid (CSF) of ΑD
subjects at higher levels than non-demented control subjects (48 - 50).
AFM is an established method for characterizing and visually distinguishing between
non-aggregated, oligomeric, and fibrillar preparations of Aβ42 peptide (32, 49). Other
methods used to assess the aggregation state of Aβ42 include thioflavin T (ThT)
fluorescence, circular dichroism (CD), SDS-PAGE, and size-exclusion chromatography
(SEC), but their application, with the exception of SEC, was of limited value in the
context of the current study. Ultraviolet CD is a method for determining the secondary
structure of proteins through the analysis of dynamic light scattering (51). Both
oligomeric and fibrillar aggregates of Aβ42 elicit CD spectra indicative of a β-sheet
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secondary structure, while HFIP treatment yields monomeric Aβ42, which exhibits an αhelical conformation (52). Incorporation of the benzothiazole dye ThT into the β-sheet
structure of Aβ42 aggregates results in an increase and spectral shift in its fluorescent
emission, making it ideal for amyloid plaque histology of AD brain and measuring the
rate of Aβ aggregation (53, 54). ThT fluorescence and CD can discriminate between
solutions containing non-aggregated and aggregated forms of Aβ42, but can not be used
to differentiate between solutions containing oligomeric and fibrillar aggregates due to
their common secondary structure. SDS-PAGE, although widely used to characterize
Aβ42 aggregates, produces nearly identical electrophoretic profiles regardless of
preparation, either non-aggregated, oligomeric, or fibrillar Aβ42, and the presence of
SDS alters the distribution of the peptide amongst different molecular weight
aggregates (49). SEC, in combination with a method for cross-linking and therefore
stabilizing oligomeric aggregates of Aβ42 of specific n-mer would have been useful for
extending the current study. High-resolution SEC, coupled with multiangle laser light
scattering analysis allows for the separation and precise determination of the molecular
weight of Aβ42 oligomers (49). Photo- and chemically-induced cross-linking of Aβ42
oligomers has been performed successfully (55, 56). The combination of photo- or
chemically-induced cross-linking and SEC would have potentially allowed for the
isolation and identification of oligomeric species of Aβ42 responsible for the activation
of ERK/MAPK.
Oligomeric aggregates of Aβ42, but neither fibrillar aggregates of Aβ42 or nonaggregated Aβ42, led to activation of the ERK/MAPK signalling pathway in SH-SY5Y cells.
Although ERK1/2 phosphorylation was not as robust in response to oligomeric Aβ42 as
to NGF, this study demonstrates phosphorylation of ERK1/2 in response to oligomeric
Aβ42 as a consequence of dose and time, at concentrations of Aβ42 within the range
measured in the CSF of AD subjects (57 - 59). NGF activates ERK/MAPK through its
cognate receptors, the low-affinity neurotrophin receptor, p75NTR (60) and the highaffinity neurotrophin tyrosine kinase receptor type 1, TrkA (61). The concentration of
NGF in CSF is circa 1 pg/mL (62). SH-SY5Y cells express both TrkA and p75NTR (63, 64)
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and will respond to 100 ng/mL NGF to activate ERK/MAPK (65). We treated SH-SY5Y
cells with 50 ng/mL of NGF as a positive control for phosphorylation of ERK1/2 and were
required to reduce the amount of protein resolved by SDS-PAGE by half, compared to
Aβ42 treated and control cells, to avoid over-exposure of immunoblots due to the
intensity of NGF-stimulated phosphorylated-ERK1/2 bands. The concentration of Aβ42
in the CSF of individuals diagnosed with AD, as measured by enzyme-linked
immunosorbent assay, is 50 – 200 nM (57 - 59). In SH-SY5Y cells, oligomeric Aβ42
acutely induced phosphorylation of ERK1/2 at a concentration of 100 nM, which peaked
after 10 min incubation. These results are similar to those of Dineley et al. when they
examined ERK/MAPK activation in hippocampal slice cultures in response to Aβ42
peptides (23). They observed maximal induction of ERK1/2 phosphorylation at an
earlier time point, after 5 min incubation with 100 nM Aβ42. However, this study was
performed with solutions of synthetic Aβ42 peptides that were not characterized in
terms of the different structural forms or aggregates of Aβ42 that may have been
present to contribute to these effects. Our findings of Aβ42-induced activation of
ERK1/2 differ from those of Townsend et al. and Ma et al. in which they observed
inhibition of the ERK/MAPK signalling pathway through insulin receptor- or insulin-like
growth factor receptor-dependent mechanisms, respectively (66, 67). Several critical
factors could account for the differences between experimental responses, most
notably the time frames from the exposure to Aβ prior to monitoring for ERK1/2
activation and the aggregation state and concentrations of Aβ tested.
In our analysis, oligomers 3.0 - 3.8 nm in height comprised the majority of the
aggregates in oligomeric preparations of Aβ42. We noted the presence of a second
smaller population of aggregates on the order of 2 nm in height, an aggregate species
that was also apparent, to a small degree, as oligomers within fibrillar preparations. The
presence of oligomers within fibrillar preparations may have been responsible for the
slight activation of ERK/MAPK observed in our experiments. However, since we did not
observe significant changes in the phosphorylation of ERK1/2 in response to the
application of fibrillar preparations of Aβ42, this suggests the aggregate species which
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are capable of activating ERK1/2 were absent from this preparation. Oligomers of Aβ42
in the range of 3.0 - 3.8 nm in height, which appeared with the greatest frequency in
oligomeric preparations and were absent from fibrillar preparations, may represent the
structural form of the peptide responsible for the activation of ERK1/2 in SH-SY5Y cells.
The sensitivity of oligomeric Aβ42-induced phosphorylation of ERK1/2 to MLA suggests a
role for the α7 nAChR in mediating activation of this pathway. SH-SY5Y cells express
functional α7 nAChR (36, 68) and have been previously used to elucidate the role of the
α7 nAChR in activation of the ERK/MAPK signalling pathway by the nAChR agonist
nicotine (42). MLA is a competitive antagonist selective for the α7 nAChR (69, 70).
Incubation of SH-SY5Y cells with 10 nM MLA prior to the addition of oligomeric Aβ42
mitigated the peptide-stimulated increase in phosphorylation of ERK1/2 above basal
levels. These findings are in support of those made by Bell et al. that 1 μM MLA blocked
Aβ42-induced activation of ERK/MAPK in hippocampal slice cultures (24). The
dissociation constant (Kd) of MLA for the α7 nAChR is approximately 2 nM (70). If a
higher concentration of MLA, on the order of 100 to 1000-fold Kd (0.2 - 2 µM) to ensure
maximal receptor binding, had been used in our experiments, we may have observed
significant blockade of oligomeric Aβ42-induced phosphorylation of ERK1/2 and our
results would have perhaps been more in line with that of Bell and colleagues. These
results demonstrate that the α7 nAChR is a mechanism through which Aβ42 oligomers
can activate the ERK/MAPK signalling pathway. The p75NTR has also been identified as
a receptor for oligomeric aggregates of Aβ42 and subsequent activation of ERK/MAPK.
A low concentration, 25 nM of low n-mer Aβ42 aggregates induces acute
phosphorylation of ERK1/2 within 5 min in cells stably transfected with p75NTR (71). As
SH-SY5Y cells endogenously express p75NTR (64) and interaction between oligomeric
Aβ42 and p75NTR could have affected our investigation, antisense silencing of
α7 nAChR mRNA through transfection of SH-SY5Y cells with small interfering RNA (72,
73) prior to cell treatments would have been useful for determining the contribution of
α7 nAChR to phosphorylation of ERK1/2 in oligomeric Aβ42 treated cells. Directly
upstream of ERK1/2 in the ERK/MAPK pathway, activation of MEK1/2 is required for
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phosphorylation and activation of ERK1/2 (47). U0126 is an inhibitor of MEK1/2 that
prevents phosphorylation of ERK1/2 (74). Blockade of oligomeric Aβ42-induced
phosphorylation of ERK1/2 by U0126 suggests that oligomeric aggregates of Aβ42 are
capable of activating ERK/MAPK in SH-SY5Y cells through the upstream activator
MEK1/2. Based on these finding, we would propose a signalling pathway for oligomeric
Aβ42 that leads from α7 nAChR to the phosphorylation of ERK1/2 through MEK1/2,
involving an undetermined mechanism that transduces signals from α7 nAChR to
MEK1/2 (Figure 2.8).
Our findings reinforce the widely held hypothesis that small oligomers of Aβ42, rather
than Aβ42 fibrils or non-aggregated Aβ42, represent the biologically active form of the
peptide. This relationship to the activity of oligomeric Aβ42 extends to effects on a wide
variety of other important cellular processes (75), including regulation of calcineurin
activity (76); production of brain-derived neurotrophic factor (77); protein kinase C
activity (78); MAPK kinase 6 expression (79); ERK/MAPK-dependent neuronal
differentiation of bone marrow-derived mesenchymal stem cells (80), and cellular prion
protein signalling and trafficking (81 - 83). Activation of ERK/MAPK by soluble diffusible
oligomers of Aβ42, similar to those we observed in oligomeric preparations of synthetic
Aβ42, may play a role in the disruption of cognitive function in AD. Oligomeric
aggregates of Aβ42 acutely activate the ERK/MAPK signalling pathway through a
mechanism that involves the α7 nAChR and is dependent upon MEK1/2 activity. The
α7 nAChR has an emerging role in learning and memory processes (84). Given the
increasing relevance of the α7 nAChR to cognitive function and the importance of
ERK/MAPK to these processes, the results of this study place an emphasis on identifying
the structural forms of Aβ42 peptides which may interact with the α7 nAChR and the
signalling consequences that result.
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Figure 2.8 A model for oligomeric Aβ42 signalling through the α7 nAChR.
Oligomeric Aβ42, but neither non-aggregated or fibrillar Aβ42, induces phosphorylation of
ERK1/2 through the α7 nAChR. Phosphorylation of ERK1/2 is mitigated by the α7 nAChRselective antagonist, MLA, and completely blocked by U0126, an inhibitor of MEK1/2. MEK1/2
acts directly upstream of ERK1/2 in the ERK/MAPK signal transduction pathway. An
undetermined signal transduction mechanism lies between α7 nAChR and MEK1/2. Legend,
inset.
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Chapter 3

3

The α7 Nicotinic Receptor is Internalized via a ClathrinIndependent, Flotillin- or Caveolin-Associated Endocytic
Pathway
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3.1 Summary
The α7 nicotinic acetylcholine receptor is a ligand-gated ion channel expressed at preand postsynaptic as well as somatodendritic sites throughout the brain, where it can
modulate activity within the neural network. The regulated endocytosis of ligand-gated
ion channels from the plasma membrane is an important mechanism for maintaining
the integrity of neurotransmission. We demonstrate that binding of the competitive
antagonist αBTX causes internalization of the α7 nAChR in HEK 293 cells and an SH-SY5Y
human neuroblastoma cell line that stably express FLAG epitope-tagged α7 nAChR.
αBTX-induced internalization of the receptor is clathrin- and dynamin-independent, and
is unaffected by putative clathrin adaptor protein binding motifs within the large
intracellular loop of the α7 nAChR subunit. Internalization is not blocked by inhibition of
actin polymerization or over-expression of dominant negative RhoGTPases or dominant
negative RalGTPase, mechanisms of clathrin-independent endocytosis. Rather, αBTX
may lead to endocytosis of α7 nAChR-αBTX complexes through alternate flotillin 1 or
caveolar 1α pathways that traffic through early and late endosomes to the lysosome.
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3.2 Introduction
The α7 nAChR is an important neuronal nAChR that modulates synaptic plasticity
underlying learning and memory processes (1). It is localized at presynaptic locations (2
- 5) as well as postsynaptic and somatodendritic sites (6 - 12). At postsynaptic locations,
it can convey cholinergic synaptic input to inhibitory interneurons in the hippocampus
(8, 9, 13) to elicit GABA release, inhibit the hippocampal network (14, 15) and block
short- and long-term potentiation (16). Alternatively, at presynaptic or somatodendritic
locations, the α7 nAChR can enhance glutamate release (3, 17) or membrane
depolarization to facilitate short- and long-term potentiation within the hippocampus
(16).
The α7 nAChR functions as a ligand-gated ion channel and exerts its modulatory effects
through calcium signalling (1). To maintain the integrity of neurotransmission, a
number of neurotransmitter receptors that function as ligand-gated ion channels
undergo regulated trafficking to control the number of cell surface receptors, and hence
the response of neurons to the surrounding neural network. The most thoroughly
studied are γ-aminobutyric acid type A receptors (GABAARs), α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid receptors (AMPARs), and N-methyl D-aspartate
receptors (NMDARs). Plasma membrane levels of GABAARs, AMPARs, and NMDARs are
each regulated by binding of clathrin adaptor protein AP2 and clathrin and dynamin
mediated endocytosis (18 - 20). GABAARs and AMPARs undergo constitutive recycling,
with receptor turnover occurring within minutes (18, 19), while NMDAR as well as
AMPAR endocytosis occurs in response to ligand binding (20, 21).
In this study, we demonstrate ligand-induced internalization of the α7 nAChR transiently
expressed in HEK 293 human embryonic kidney cells and stably expressed in SH-SY5Y
human neuroblastoma cells. The competitive antagonist, αBTX induces endocytosis of
α7 nAChR in both HEK 293 and SH-SY5Y cells. The endocytic pathway of α7 nAChR-αBTX
complexes differs from clathrin-dependent endocytosis because internalization of the
receptor is not blocked by expression of a dominant negative isoform of dynamin or
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disruption of the clathrin-coat. Endocytosis is unaffected by inhibition of actin
polymerization or by dominant negative isoforms of RhoGTPases. αBTX appears to
induce internalization of the α7 nAChR through flotillin 1 or caveolin 1α-positive
pathways that traffic the receptor through late endosomes to lysosomes.

3.3 Methods
3.3.1

Materials

HEK 293 cells and SH-SY5Y cells were provided by American Type Culture Collection
(Manassas, VA). DMEM, Eagle’s minimal essential medium with Earle’s salts (MEM),
FBS, the pcDNA3.1(+) mammalian expression vector, Lipofectamine 2000, Geneticin
(G418), αBTX, Alexa Fluor 647-conjugated αBTX, Alexa Fluor 546-conjugated goat antirabbit IgG antibody, Alexa Fluor 546-conjugated donkey anti-mouse IgG antibody, Alexa
Fluor 633 transferrin, 4’,6-diamidino-2-phenylindole (DAPI) dilactate, and cytochalasin D
were obtained from Invitrogen (Burlington, ON). DMSO and polyclonal rabbit anti-FLAG
antibody were obtained from Sigma-Aldrich Canada (Oakville, ON). Monoclonal mouse
anti-EEA1 antibody was from BD Biosciences (Mississauga, ON). Monoclonal mouse
anti-LAMP1 (H4A3) was from Abcam (Cambridge, MA). Monoclonal mouse anti-HA
antibody (12CA5) was from Roche (Laval, QC). Polyclonal rabbit anti-α7 nAChR antibody
(H-302) was from Santa Cruz Biotechnology (Santa Cruz, CA). HRP-conjugated goat antirabbit IgG secondary antibody was from Jackson ImmunoResearch Laboratories (West
Grove, PA). HRP-conjugated sheep anti-mouse IgG secondary antibody and ECL western
blotting detection reagent were from GE Healthcare (Baie d’Urfé, QC). Immuno-Blot
polyvinylidene fluoride (PVDF) membrane was from Bio-Rad Laboratories (Mississauga,
ON). X-OMAT LS film was from Eastman Kodak (Toronto, ON). Shandon Immu-mount,
EZ-Link sulfo-NHS-SS-biotin and NeutrAvidin Agarose were from Thermo Fisher Scientific
(Waltham, MA).

75

3.3.2

DNA Constructs and Site-Directed Mutagenesis

All recombinant cDNA procedures were carried out following standard protocols. The
sequence for each oligonucleotide primer is listed in Table 3.1. The cDNA for the
α7 nAChR subunit was cloned from a QUICK-Clone™ human universal cDNA library
(Clontech Laboratories, Mountain View, CA) by PCR using 5’-oligonucleotide primers
(α7-fwd) and 3’-oligonucleotide primers (α7-rev) designed from the NCBI Reference
Sequence NM_000746.3 in the GenBank database. 5’-Oligonucleotide primers (α7BamHI-fwd) introduced an amino-terminal BamHI restriction site, and 3’-oligonucleotide
primers (α7-XbaI-rev) introduced a carboxyl-terminal Xba I site to allow sub-cloning of
the PCR product into pcDNA3.1(+). 3’-Oligonucleotide primers (α7-FLAG-rev) introduced
a FLAG epitope (DYKDDDDK) to the carboxyl-terminal of the PCR product for sub-cloning
of a FLAG epitope-tagged α7 nAChR subunit cDNA (FLAG-α7 nAChR) into pcDNA3.1(+).
The cDNA for human RIC3, matching the GenBank NCBI Reference Sequence
NM_024557, was purchased from Origene (Rockville, MD). 5’-Oligonucleotide primers
(hRIC3-KpnI-fwd) introduced an amino-terminal Kpn I restriction site, and 3’oligonucleotide primers (hRIC3-NotI-HA-rev) introduced a carboxyl-terminal influenza
haemagglutinin (HA) epitope tag (YPYDVPDYA) and Not I restriction site to allow subcloning of an HA epitope-tagged hRIC3 (HA-hRIC3) cDNA into pcDNA5/FRT (Invitrogen,
Burlington, ON). Mutant isoforms of FLAG-α7 nAChR, Y386A/F389A, Y386F/F389A,
L420A/L421A, and D417A/L420A/L421A were generated by sequential PCR (22). GFPRab4, GFP-Rab5, GFP-Rab7, GFP-Rab11, YFP-RhoA T19N, YFP-Rac1 T17N, GFP-Cdc42
T17N, YFP-RalA S28N, dynamin 1 K44A, and AP180-C constructs were kindly provided by
Stephen Ferguson. Flotillin 1-GFP and caveolin 1α-GFP constructs were a generous gift
from Marco Prado. All plasmids were confirmed by DNA sequencing to ensure the
presence of restriction sites, fluorescent or epitope tags, and mutations; that cDNA
sequences were in the correct orientation for expression, and no other mutations had
been introduced by PCR.
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Table 3.1 Oligonucleotide primers used in cloning and sub-cloning of the human
α7 nAChR subunit and hRIC3 cDNA.
Primer

Sequence (5’ – 3’)

α7-fwd
α7-rev
α7-BamHI-fwd
α7-XbaI-rev
α7-FLAG-rev

CGACAGCCGAGACGTGGA
CCGATGGTACGGATGTGC
GCCGGGATCCGCCACCGGGACTCAACATGCGCTG
AGACTTTGCGTAACCACGCCTCTAGAGCCG
CGGCTCTAGATTACTTGTCGTCGTCGTCCTTATAGTCCGCAAAGTCTTTGGACA
CGGCC
CGGCGGTACCGCCACCATGGCGTACTCCACAGTGCAGAGAGTC
GCGGCCGCCAACTCACGCATAATCCGGCACATCATACGGATACTCTAAACCCT
GGGGGTTACGCTTCCT

hRIC3-KpnI-fwd
hRIC3-NotI-HA-rev

3.3.3

Cell Model

Human embryonic kidney 293 (HEK-293) cells present a flat surface area conducive to
transfection as well as a large area of cytoplasm relative to their nuclei beneficial for the
observation of intracellular proteins by confocal microscopy. The HEK 293 cell line was
developed by transforming primary cultures of human embryonic kidney cells with
adenovirus (23). HEK-293 cells have been used extensively in studies requiring
transfection and heterologous expression of proteins (24), including the endocytosis and
trafficking of transmembrane proteins (25, 26). HEK 293 cells are limited by their
inability to heterologously express functional α7 nAChR, this is overcome by cotransfection with cDNA for the nAChR chaperone protein RIC3 (27).
The SH-SY5Y cell line is a human cell line sub-cloned from the SK-N-SH cell line (28),
originally isolated from a human metastatic neuroblastoma (29). SH-SY5Y cells
endogenously express α3, α5, α7, β2 and β4 nAChR subunits (30, 31) as well as the
chaperone protein RIC3 (27). SH-SY5Y cells have small, round cell bodies with little
cytoplasm (28) making them difficult to transfect, requiring isolation of stably
transfected clones for studies involving heterologously expressed proteins and limiting
their use for confocal microscopy.
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3.3.4

Cell Culture and Transfection

HEK 293 cells were grown in MEM containing 10% (v/v) FBS at 37 °C in humidified air
with 5% CO2. Cells were seeded at a density of 2.5 × 106 per 100 mm dish and
transiently transfected by a modified calcium phosphate method (32) with the cDNA
expression plasmids described in the figure legends. Following transfection
(approximately 18 h), cells were pooled and collected for immunoblotting or reseeded
onto 15 mm collagen-coated glass cover slips in 12-well plates for receptor
internalization experiments or immunocytochemistry. SH-SY5Y-FLAG-α7 cells,
expressing FLAG-α7 nAChR protein and the neomycin resistance gene, and SH-SY5Y-Neo
cells, expressing only the neomycin resistance gene, were generated by transfecting SHSY5Y cells with FLAG-α7 nAChR cDNA in pcDNA3.1(+) and empty vector pcDNA3.1(+)
DNA, respectively, with Lipofectamine 2000, following the manufacturer’s protocols.
Briefly, SH-SY5Y cells, 70% confluent in 35 mm dishes, were transfected as described
and cultured for 48 h prior to being diluted 1:8 into 100 mm dishes and subsequently
cultured in the presence of 2 mg/mL G418 until individual foci of neomycin resistant
clonal cells had grown. Isolated foci were transferred to single wells of a 48-well plate
and each was separately cultured up to a 75 cm2 flask upon which clones were selected
based on growth rate and protein expression. Positive clones were maintained in
DMEM, 10% (v/v) FBS, 0.2 mg/mL G418 at 37 °C in humidified air with 5% CO2. SH-SY5YFLAG-α7 cells were identified by binding of Alexa Fluor 647-conjugated αBTX. Stable
integration of the neomycin resistance gene into the genome of SH-SY5Y-Neo cells was
determined by reverse-transcriptase PCR amplification of a neomycin resistance gene
795 bp fragment using 5’-oligonucleotide (5’-ATGATTGAACAAGATGGATTCCACGC-3’)
and 3’-oligonucleotide (5’-TCAGAAGAACTCGTCAAGAAGGCG-3’) primers. The same
clone, of either SH-SY5Y-FLAG-α7 cells or SH-SY5Y-Neo cells, was used throughout
experiments.
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3.3.5

Immunoblotting

Cells were collected following transfection, washed with PBS (138 mM NaCl, 2.7 mM
KCl, pH 7.4), lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Triton X100, 1 mM AEBSF, 10 mM NaF, 500 nM NaVO4, 10 mg/mL leupeptin, 25 mg/mL
aprotinin, and 10 mg/mL pepstatin A) and rotated at 4 °C for 30 min. The protein
concentration of each lysate was determined by the method of Bradford (33). Equal
amounts of protein (50 μg per sample) were resolved on 10% polyacrylamide gels by
SDS-PAGE according to the method of Laemmli (34). Separate sets of protein samples
were resolved for each antibody to be blotted and transferred to separate PVDF
membranes. Membranes were probed with primary anti-FLAG antibody (1:1000), antiα7 nAChR antibody (1:200), or anti-HA antibody (1:1000) and HRP-conjugated antirabbit or anti-mouse IgG secondary antibodies (1:20,000 or 1:5000), followed by
detection of immunoreactive protein bands with ECL reagent and film.

3.3.6

Fluorescent α-Bungarotoxin Internalization and Co-localization

For labelling and internalization of FLAG-α7 nAChR expressed in HEK 293 and SH-SY5YFLAG-α7 cells, cells were reseeded onto collagen-coated glass cover slips, then washed
with chilled HEPES-buffered salt solution (HBSS) (1.2 mM KH2PO4, 5 mM NaHCO3,
20 mM HEPES, 11 mM D-glucose, 116 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM
CaCl2, pH 7.4) and incubated with 500 nM of Alexa Fluor 647-conjugated αBTX in HBSS
0.1% BSA for 1 h on ice. The Kd of αBTX is 0.4 - 0.6 nM for the α7 nAChR (35, 36), and a
concentration of 500 nM, roughly 1000-fold Kd, was deemed sufficient to saturate
receptor binding sites present on HEK 293 and SH-SY5Y cells. Cover slips were washed
with HBSS to remove excess unbound fluorescent αBTX and transferred to cell culture
medium at 37 °C for the specified time. At the end of the incubation period, cover slips
were washed with chilled HBSS containing 0.1% BSA and incubated in the same with
rabbit anti-FLAG antibody (1:1000) for 1 h on ice. Cells were washed and subsequently
incubated with Alexa Fluor 546-conjugated goat anti-rabbit secondary antibody (1:1000)
in HBSS 0.1% BSA for 1 h on ice, washed and then fixed with chilled PLP (periodate 0.2%,
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lysine 1.4%, paraformaldehyde 2%) (37) for 20 min on ice. To stain nucleic acids, fixed
cells were incubated with 300 nM DAPI in PBS for 5 min and washed before mounting
onto microscope slides with Immu-mount. Alternatively, cells were fixed following
incubation with primary anti-FLAG antibody and stored overnight at 4 °C in PBS before
being blocked with PBS containing 10% BSA and incubated with Alexa Fluor 546conjugated secondary antibody in PBS containing 3% BSA and mounted for microscopy.
To examine co-localization with EEA1 and LAMP1, HEK 293 cells were incubated with
Alexa Fluor 647-conjugated αBTX in HBSS containing 0.1% BSA for 1 h on ice, then
washed and transferred to cell culture medium at 37 °C for the specified time. At the
end of the incubation period, cells were transferred to ice, fixed with chilled PLP and
stored overnight at 4 °C in PBS. To detect endogenous EEA1 and LAMP1 proteins, cells
were permeabilized with PBS containing 0.25% Triton X-100 for 5 min, blocked with PBS
containing 10% BSA for 30 min, washed, and then incubated with anti-EEA1 or antiLAMP1 antibodies (1:1000) in PBS containing 3% BSA for 1 h at room temperature.
Primary antibody-labelled cells were incubated with Alexa Fluor 546-conjugated donkey
anti-mouse IgG secondary antibody (1:1000) in PBS containing 3% BSA and 6% normal
goat serum before washing and mounting cover slips to microscope slides. For HEK 293
cells co-transfected with RabGTPases, 500 nM Alexa Fluor 647 αBTX was added directly
to cell cultures at 37 °C and cells were incubated in its presence for 2 h, before being
washed and fixed on ice with chilled PLP. In HEK 293 cells co-transfected with flotillin 1GFP and caveolin 1α-GFP, cells were incubated with Alexa Fluor 647-conjugated αBTX in
HBSS containing 0.1% BSA for 1 h on ice, then washed and transferred to cell culture
medium for 2 h at 37 °C, following which they were returned to ice and fixed with
chilled PLP.

3.3.7

Clathrin and Dynamin Inhibition

To determine if inhibition of clathrin-dependent endocytosis blocked receptor
internalization, HEK 293 cells were co-transfected with FLAG-α7 nAChR and HA-hRIC3
and either dominant negative dynamin 1 K44A or AP180-C, then labelled with 500 nM
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Alexa Fluor 647-conjugated αBTX in HBSS containing 0.1% BSA for 1 h on ice, washed,
and transferred to cell culture medium at 37 °C for 6 h. In some experiments, Alexa
Fluor 633-conjugated transferrin was added to the cell culture media 20 min before the
end of the incubation period to assess functional expression of dynamin 1 K44A or
AP180-C. At the end of the incubation, cells were washed with ice-cold HBSS and fixed
with chilled PLP on ice before mounting for microscopy.

3.3.8

Cytochalasin D Treatment and RhoGTPase Inhibition

To determine the effect of inhibition of actin polymerization on receptor internalization,
HEK 293 cells co-transfected with FLAG-α7 nAChR and HA-hRIC3 were incubated with
500 nM Alexa Fluor 647-conjugated αBTX in HBSS containing 0.1% BSA for 1h on ice,
then washed and transferred to cell culture medium containing 2.5 μM cytochalasin D
or an equivalent volume of DMSO vehicle and incubated at 37 °C for 2 or 4 h. At the end
of the incubation period, cells were washed with ice-cold HBSS, and incubated with
rabbit anti-FLAG antibody in HBSS containing 0.1% BSA for 1 h on ice. Primary anti-FLAG
antibody binding was detected by subsequently incubating cells with Alexa Fluor 546conjugated goat anti-rabbit IgG secondary antibody in HBSS containing 0.1% BSA for 1 h
on ice. Cells were washed and fixed with chilled PLP on ice for 20 min before mounting
for microscopy. To assess the effects of over-expression of dominant negative
RhoGTPases and RalGTPase on receptor internalization, HEK 293 cells co-transfected
with FLAG-α7 nAChR and HA-hRIC3 and either, YFP-RhoA T19N, YFP-Rac1 T17N, GFPCdc42 T17N, or YFP-RalA S28N were incubated with 500 nM Alexa Fluor 647-conjugated
αBTX in HBSS containing 0.1% BSA for 1h on ice, then washed and transferred to cell
culture medium at 37 °C for 4 h.

3.3.9

Co-localization with Flotillin 1 and Caveolin 1α

HEK 293 cells co-transfected with FLAG-α7 nAChR and HA-hRIC3 and either flotillin 1GFP or caveolin 1α-GFP were incubated with 500 nM Alexa Fluor 647-conjugated αBTX
in HBSS containing 0.1% BSA for 1 h on ice, then washed and transferred to cell culture
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medium at 37 °C for 2 h. At the end of the incubation period, cells were washed with
ice-cold HBSS, then fixed with chilled PLP for 20 min on ice and mounted for microscopy.

3.3.10

Confocal Microscopy

Confocal microscopy was performed using a Zeiss LSM-510 META -NLO laser-scanning
microscope with a Zeiss Plan-APOCHROMAT 63 × 1.4 DIC oil immersion lens. Alexa Fluor
546 fluorescence was detected by excitation with a HeNe 543 nm wavelength laser and
565 - 615 nm band-pass emission filter; Alexa Fluor 647 and Alexa Fluor 633 by
excitation with a HeNe 633 nm laser and 650 - 710 nm band-pass emission filter, and
GFP with an Argon laser with a 488 nm wavelength excitation filter and 500 - 550 nm
band-pass emission filter. DAPI was detected by excitation with a multi-photon
Chameleon Ti Sapphire laser pulsing photons at a wavelength of 870 nm and a 435 - 485
nm band-pass filter. In experiments examining the subcellular localization of Alexa Fluor
647-conjugated αBTX and Alexa Fluor 633-conjugated transferrin, emission fingerprints
for each fluorochrome were obtained individually from separate control experiments in
which HEK 293 cells had been treated with one fluorochrome-conjugated peptide or the
other. Spectral signatures were carefully adjusted by comparison to the localization of
each protein in the control samples to ensure that unmixing the overlapping spectra of
the two fluorochromes did not alter the appearance or localization of each
fluorochrome-conjugate in our experimental samples.

3.3.11

Criteria for Selection of Micrographs

In the experiments presented, we regarded each transiently transfected HEK 293 cell
individually. The rationale for this approach is that we observed varying levels of
heterologous protein expression following transfection of these cells, which could
account for varying levels of fluorescent αBTX internalization and subsequent changes
to FLAG immunofluorescence on the surface of cells. In most cases, experiments were
repeated at least once (two independent experiments) or more on cells from different
passages to ensure that observations were independent from factors that could affect
protein expression or function in a given trial. In general, greater scientific rigour would
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have been achieved by completing more than three independent experiments for each
investigation. Experiments designed to assess the time course for protein
internalization, co-localization, or the effects of dominant negative proteins were
repeated to ensure that our observations were consistent from transfection to
transfection and across cell passages. In protein co-localization experiments, we
captured images from several cells, dependent upon the efficiency of transfection, to
ensure that data reported are representative of the general population of cells from
each transfection. For each experiment, we report the minimum and maximum number
of representative micrographs recorded from each condition or time point, from one or
more coverslip replicates, which reflected our overall observations and led to our
findings.

3.4 Results
3.4.1

The Chaperone Protein, hRIC3 is Required for Functional Cell
Surface Expression of α7 nAChR in HEK 293 Cells

Expression of the α7 nAChR in HEK 293 cells was problematic until the discovery of the
protein RIC3, from the Caenorhabditis elegans gene, resistant to inhibitors of
cholinesterase (ric-3) (38). RIC3 is a transmembrane protein resident in the ER of many
neuronal cells and neuronal cell lines which co-ordinates the efficient assembly of
α7 nAChR subunits into a functional receptor pentamer (39). Co-expression of C.
elegans RIC3 or its human homologue, hRIC3, increases the responsiveness of α7 nAChR
expressed in Xenopus laevis oocytes and facilitates functional expression of α7 nAChR in
HEK 293 cells (27).
I first amplified and sub-cloned the full-length cDNA for the α7 nAChR subunit from a
human universal cDNA library using primers based on the sequence in the GenBank
database. DNA sequencing analysis revealed the coding sequence obtained is identical
to NCBI Reference Sequence NM_000746.3, except for a silent mutation, adenine 933 to
guanine, resulting in a codon change, ACA to ACG, and conservation of threonine 311.
The FLAG epitope amino acid sequence was introduced into the extracellular carboxyl-
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terminus of the α7 nAChR subunit by PCR to generate a FLAG epitope-tagged α7 nAChR,
FLAG-α7 nAChR. Addition of the FLAG epitope to the receptor delayed the rate at which
whole-cell calcium changed in response to the agonist nicotine (Appendix A).
To verify the requirement of co-expression with hRIC3 for functional expression of
α7 nAChR in HEK 293 cells, we examined binding of fluorochrome-labelled αBTX and
immunofluorescent staining of cells with anti-FLAG antibody in HEK 293 cells transfected
with cDNA for FLAG-α7 nAChR subunit and HA-hRIC3 or FLAG-α7 nAChR subunit and
empty vector DNA (Figure 3.1 A). Cells transfected with both FLAG-α7 nAChR subunit
and HA-hRIC3 bound fluorescent αBTX. Cells expressing FLAG-α7 nAChR alone were
detectable by immunofluorescent staining with anti-FLAG antibody on the cell surface
(not permeabilized) and throughout the cell (permeabilized), but did not bind
fluorescent αBTX. Cells transfected with FLAG-α7 nAChR subunit cDNA and empty
vector DNA that were not permeabilized exhibited consistent surface anti-FLAG staining
up and down throughout the Z-stack. This staining was less evident when scanning only
a thin cross-section of plasma membrane at lower to mid Z, the upper most Z sections
(top) of cells, which presented the greatest cross-sectional area of plasma membrane,
provided the strongest fluorescent signal (Figure 3.1 A, FLAG (not permeabilized)). We
did not observe binding of fluorescent αBTX or anti-FLAG immunofluorescence in cells
that had been transfected with empty vector DNA alone (data not shown).
Immunoblotting of cell lysates from cells transfected in parallel to those labelled with
fluorescent αBTX demonstrated co-expression of HA-hRIC3 protein in these cells
following transfection (Figure 3.1 B). Anti-HA antibody directed toward the HA epitope
on hRIC3 (apparent molecular weight 48 kDa) detected a single band resolving between
the 46 and 58 kDa markers. Anti-α7 nAChR antibody or anti-FLAG antibody detected
FLAG-α7 nAChR resolving as double bands above 46 kDa and higher molecular weight
bands between 80 and 175 kDa. In comparison, anti-α7 nAChR antibody detected wildtype α7 nAChR resolving as double bands at slightly lower molecular weights than those
for FLAG-α7 nAChR; the FLAG epitope amino acid sequence has an expected molecular
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Figure 3.1 The chaperone protein, hRIC3 is required for functional cell surface
expression of α7 nAChR in HEK 293 cells.
(A) HEK 293 cells transfected with FLAG-α7 nAChR subunit and HA-hRIC3 cDNA or FLAGα7 nAChR subunit cDNA and empty vector DNA were incubated on ice with 500 nM Alexa Fluor
647-αBTX in 0.1% BSA HBSS for 1 h, washed, fixed with PLP, and mounted. To detect expression
of FLAG-α7 nAChR subunit protein in the absence of co-transfection with HA-hRIC3 cDNA, cells
were fixed with PLP and either left intact (not permeabilized), to label cell surface FLAGα7 nAChR subunits, or treated with 0.25% Triton X-100 PBS (permeabilized), to label FLAGα7 nAChR subunits throughout the cell, and incubated with anti-FLAG antibody and Alexa Fluor
546-conjugated secondary antibody. Images of Alexa Fluor 647-αBTX (green) or Alexa Fluor 546conjugated secondary antibody (red) were captured from single z-sections or selected from a
series of z-sections, captured as a stack, on a laser-scanning confocal microscope. FLAG (not
permeabilized) represents the upper most Z section (top) of a cell, which presented the greatest
cross-sectional area of plasma membrane and strongest fluorescent signal. Bar, 10 µm. (B)
Crude cell lysate from cells transfected in parallel to those in A, immunoblotted with anti-FLAG,
anti-α7 nAChR, or anti-HA antibody and HRP-conjugated secondary antibody to detect
expression of FLAG-α7 nAChR, wild-type α7 nAChR and FLAG-α7 nAChR, or HA-hRIC3 proteins
respectively. Images are representative of 5 to 10 cells per treatment, per experiment, from
two independent experiments; immunoblots are representative of two independent
experiments.
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weight of 1 kDa. Anti-FLAG, anti-α7 nAChR, or anti-HA antibodies did not detect bands
resolving at these molecular weights in cells that were not transfected, and anti-FLAG
and anti-α7 nAChR antibodies did not detect bands in cells transfected with HA-hRIC3
and empty vector DNA.
The cell surface expression of FLAG-α7 nAChR in HEK 293 cells in the absence of hRIC3 is
supported by a preliminary cell surface biotinylation experiment in which FLAGα7 nAChR is detectable in Neutravidin precipitates from cells expressing FLAG-α7 nAChR
with or without co-transfection with HA-hRIC3 cDNA (Appendix B). In HEK-293 cells,
transfected with FLAG-α7 nAChR cDNA and empty vector DNA, FLAG-α7 nAChR and HAhRIC3 cDNA, or empty vector DNA and HA-hRIC3 cDNA, cell surface proteins were
detected by reaction with EZ-Link sulfo-NHS-SS-biotin and subsequent precipitation with
NeutrAvidin agarose. Sulfo-NHS-SS-biotin covalently binds preferentially to lysine amino
acid residues to form biotinylated protein conjugates (40). It is not plasma membrane
permeable and reacts with exposed lysine residues in extracellular polypeptides to
biotinylate only cell surface proteins when incubated with intact cells (40). The
α7 nAChR subunit contains 13 lysine residues in extracellular domains, potentially
available for reaction with sulfo-NHS-SS-biotin, based on topological and
transmembrane domain predictions provided by UniProt Knowledgebase reference
P36544 (UniProt Consortium). The FLAG epitope, appended to the extracellular
carboxyl-terminus of FLAG-α7 nAChR subunit, may provide an additional two lysine
residues.
Immunoblotting with anti-FLAG antibody detected FLAG-α7 nAChR resolving as double
bands circa 46 kDa and as higher molecular weight bands between 80 and 175 kDa in
biotinylated fractions, containing only cell surface proteins, as well as crude cell lysates.
FLAG-α7 nAChR immunoreactivity was noticeably increased, especially circa 46 kDa, in
the biotinylated fraction of cells that were co-transfected with HA-hRIC3 cDNA.
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3.4.2

α-Bungarotoxin Induces Internalization of the α7 nAChR

αBTX is an 8 kDa peptide isolated from the venom of the Many-banded krait, Bungarus
multicinctus (41). It is an established subtype-selective nicotinic antagonist (42). α7- ,
α8-, and α9-containing nAChR, muscle nAChR, and nAChR of Torpedo californica and
Electrophorus electricus are the only nAChR that bind αBTX with near covalent affinity
(42 - 48). When HEK 293 cells are co-transfected with plasmids encoding FLAGα7 nAChR and HA-hRIC3, FLAG-α7nAChR can be detected on the cell surface with
fluorescent αBTX or anti-FLAG antibody. To investigate whether αBTX binding affects
α7 nAChR internalization, we employed a pulse-chase paradigm (Figure 3.2).
Transfected HEK 293 cells were incubated on ice with a saturating concentration of
fluorescent αBTX, washed, transferred to 37 °C for 0, 1, 2, 4, or 6 h, and then returned
to ice and subsequently incubated with anti-FLAG antibody and fluorescent secondary
antibody, directed toward the FLAG antibody, to detect the level of FLAG-α7 nAChR
remaining on the cell surface. From 0 through 6 h, fluorescent αBTX was observed to
internalize from the cell surface and gradually accumulate into intracellular puncta that
accumulated in perinuclear regions (Figure 3.3 A, + αBTX). Coincident with the
internalization of fluorescent αBTX was an apparent loss of cell surface levels of FLAGα7 nAChR, detected by anti-FLAG antibody and secondary antibody fluorescence. In the
absence of αBTX, the levels of FLAG-α7 nAChR on the cell surface did not appear to
change over time at 37 °C (Figure 3.3 A, - αBTX). HEK 293 cells transfected with HAhRIC3 cDNA and empty vector DNA did not bind anti-FLAG antibody and fluorescent
secondary antibody or bind or accumulate internalized fluorescent αBTX after 0 or 6 h at
37 °C (Figure 3.3 B). To test whether anti-FLAG antibody was detecting the emergence
of new α7 nAChR on the cell surface following αBTX-induced internalization, we
incubated cells with fluorescent αBTX following a pulse-chase with unlabelled αBTX
(Appendix C). HEK 293 cells transfected with cDNA for FLAG-α7 nAChR and HA-hRIC3
were incubated with a saturating concentration of unlabelled αBTX on ice, washed,
transferred to 37 °C for 0 or 6 h, and then returned to ice and subsequently incubated
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Figure 3.2 Pulse-chase method for investigating αBTX-induced internalization of α7
nAChR.
(i) Transfected cells, seeded onto glass coverslips and maintained at 37 °C, were washed with
chilled HBSS and transferred to ice to cool the cells and slow plasma membrane trafficking
events. While on ice, the cells were incubated with 500 nM Alexa Fluor 647-αBTX in chilled
HBSS 0.1% BSA for 1 h to label cell surface α7 nAChR. (ii) Following surface labelling, cells were
washed with chilled HBSS to remove unbound Alexa Fluor 647-αBTX and then transferred to
warm cell culture medium and maintained at 37 °C for 0,1,2,4, or 6 h to allow receptor
internalization events to occur. (iii) Cells were then returned to ice and washed with chilled
HBSS to again slow trafficking events before sequential incubation with anti-FLAG antibody and
Alexa Fluor 546-conjugated secondary antibody to label FLAG-α7 nAChR that remained on the
cell surface. Following antibody labelling, glass coverslips were fixed and mounted for confocal
microscopy.
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Figure 3.3 αBTX binding induces internalization of α7 nAChR.
(A) HEK 293 cells transfected with FLAG-α7 nAChR and HA-hRIC3 cDNA were incubated on ice
for 1 h with (+ αBTX) or without (- αBTX) Alexa Fluor 647-αBTX, washed and transferred to 37 °C
for 0, 1, 2, 4 or 6 h. At the end of the incubation, the cells were returned to ice and incubated
with anti-FLAG antibody, followed by secondary Alexa Fluor 546-conjugated antibody directed
against the anti-FLAG antibody. The cells were fixed with PLP and nuclei were stained with DAPI
prior to mounting. Images of secondary Alexa Fluor 546-conjugated antibody (red), Alexa Fluor
647-αBTX (green), and DAPI (blue) were collected from single z-sections on a laser-scanning
confocal microscope and colour combined. (B) HEK 293 cells transfected with empty vector
DNA and HA-hRIC3 cDNA, chased with Alexa Fluor 647-αBTX for 0 or 6 h followed by antibody
incubations as in A, were used to assess non-specific binding of Alexa Fluor 647-αBTX and antiFLAG antibody. Images are representative of 5 to 30 cells per time point, per experiment, one
to three cover slips per time point, from four independent experiments. Bar, 10 µm.
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with fluorescent αBTX. After 0 h, no cells bound fluorescent αBTX; after 6 h at 37 °C, a
fraction of cells showed a small amount of fluorescent αBTX labelling.
To investigate if αBTX induces internalization of α7 nAChR in a cell line that
endogenously expresses nAChR, we examined FLAG-α7 nAChR endocytosis in SH-SY5Y
cells. For the purpose of these experiments, we generated an SH-SY5Y cell line that
stably expresses the FLAG-α7 nAChR subunit, SH-SY5Y-FLAG-α7, and a neomycin
resistant control cell line, SH-SY5Y-Neo, which expresses the neomycin resistance gene.
When SH-SY5Y-FLAG-α7 cells were incubated with fluorescent αBTX on ice and
transferred to 37 °C, fluorescent αBTX internalized as intracellular puncta similar to
what was observed in HEK 293 cells (Figure 3.4 A, + αBTX). This indicates that both HEK
293 cells and SH-SY5Y-FLAG-α7 cells exhibit αBTX induced internalization of the
α7 nAChR, suggesting the use of HEK 293 cells as a suitable model to study αBTX
induced internalization of the receptor. However, changes to cell surface levels of FLAGα7 nAChR, detected by anti-FLAG antibody and secondary antibody fluorescence were
not as apparent in SH-SY5Y-FLAG-α7 cells as for HEK 293 cells. In the absence of αBTX,
there was no change to cell surface anti-FLAG immunofluorescence over time at 37 °C
(Figure 3.4 A, - αBTX). SH-SY5Y-Neo cells did not bind anti-FLAG antibody and
fluorescent secondary antibody and did not bind or internalize fluorescent αBTX after 0
or 6 h at 37 °C (Figure 3.4 B). αBTX appears to induce internalization of the α7 nAChR
upon binding and lead to its accumulation in perinuclear regions of the cell.

3.4.3

α7 nAChR-αBTX Complexes Traffic Through Late Endosomes to
Lysosomes

To investigate the fate of α7 nAChR-αBTX complexes that have been internalized by
endocytosis and identify which membrane compartments these complexes traffic
through, we examined the kinetics of co-localization of fluorescent αBTX-labelled
α7 nAChR with early and late endosomal membrane markers. HEK 293 cells transfected
with FLAG-α7 nAChR and HA-hRIC3 cDNA were incubated on ice with fluorescent αBTX,
washed, transferred to 37 °C for 0, 1, 2, 4 or 6 h, fixed, permeabilized, and then labelled
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Figure 3.4 αBTX induces internalization of α7 nAChR in neuronal cells.
(A) SH-SY5Y-FLAG-α7 cells stably expressing FLAG-α7 nAChR were incubated on ice for 1 h with
(+ αBTX) or without (- αBTX) Alexa Fluor 647-αBTX, washed and transferred to 37 °C for 0, 1, 2, 4
or 6 h. At the end of the incubation, the cells were returned to ice and incubated with anti-FLAG
antibody, followed by secondary Alexa Fluor 546-conjugated antibody directed against the antiFLAG antibody. Images of secondary Alexa Fluor 546-conjugated antibody (red) and Alexa Fluor
647-αBTX (green) were collected from single z-sections on a laser-scanning confocal microscope
and colour combined. (B) Neomycin resistant SH-SY5Y cells, chased with Alexa Fluor 647-αBTX
as in A for 0 or 6 h, were used as a control for non-specific binding of Alexa Fluor 647-αBTX and
anti-FLAG antibody. Images are representative of 30 cells per time point, per experiment, one
to two cover slips per time point, from two independent (+αBTX) and a preliminary experiment
(-αBTX). Bar, 10 µm.
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with antibodies directed toward early-endosomal autoantigen 1 (EEA1) or lysosomalassociated membrane protein 1 (LAMP1) and fluorescent secondary antibodies. EEA1 is
involved in docking of vesicles to early endosomes (49 - 51). LAMP1 is a major
lysosomal membrane protein required for maintaining lysosome integrity (52, 53).
Fluorescent αBTX co-localized with EEA1 after 1 to 2 h, with some co-localized puncta
visible as late as 4 h, while co-localization with LAMP1 only occurred after 2 h (Figure
3.5). After 2 h, fluorescent αBTX increasingly co-localized with LAMP1 positive vesicles
from 4 to 6 h as α7 nAChR-αBTX complexes appeared to accumulate in this membrane
compartment. Lysosomes appear to represent the final destination for α7 nAChR,
following their removal from the cell surface in response to binding αBTX.
RabGTPases are small G-proteins that regulate the traffic of membrane-bound
organelles to specific membrane compartments (54). We examined co-localization of
fluorescent αBTX with the green fluorescent protein (GFP)-tagged RabGTPases, Rab4,
Rab5, Rab7 and Rab11 to determine the involvement of these proteins in the trafficking
of α7 nAChR-αBTX complexes. Rab4, Rab5 and Rab11 are localized to early endosomes
and participate in the endocytic recycling of membrane proteins, while Rab7 regulates
the traffic of membrane organelles through late endosomes to lysosomes (55 - 61). HEK
293 cells transfected with FLAG-α7 nAChR and HA-hRIC3 cDNA were incubated with
fluorescent αBTX for 2 h at 37 °C to allow for the internalization and accumulation of
α7 nAChR-αBTX complexes. Fluorescent αBTX did not co-localize with GFP-Rab4, -Rab5,
or -Rab11, suggesting that these complexes do not undergo recycling back to the cell
surface (Figure 3.6). However, fluorescent αBTX did co-localize with GFP-Rab7 puncta,
indicating that α7 nAChR-αBTX complexes traffic through Rab7-positive late endosomes
to lysosomes (Figure 3.6).

3.4.4

Canonical Endocytic Receptor Trafficking Motifs Do Not Alter Cell
Surface Expression or Endocytosis of α7 nAChR

The predicted amino acid sequence of the large intracellular loop between TM3 and
TM4 of the human α7 nAChR subunit (318 - 469) was identified from the UniProt
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Figure 3.5 α7 nAChR-αBTX complexes traffic to late endosomes.
HEK 293 cells transfected with FLAG-α7 nAChR and HA-hRIC3 cDNA were incubated on ice for
1 h with Alexa Fluor 647-αBTX, washed and transferred to 37 °C for 0, 1, 2, 4, or 6 h. The cells
were fixed, permeabilized, and labelled with antibodies directed towards specific markers EEA1
(early endosomes) and LAMP1 (lysosomes), followed by secondary Alexa Fluor 546-conjugated
antibody. Images of Alexa Fluor 647-αBTX (green) and organelle markers (red) were collected
from single z-sections on a laser-scanning confocal microscope and colour combined. Note that
α7 nAChR-αBTX complexes co-localize initially with EEA1 and, after a chase of 4 or 6 h, localize
extensively with LAMP1. Insets show magnified images of the areas indicated by an arrowhead
for Alexa Fluor 647-αBTX (green) with EEA1 or LAMP1 (red) and an overlay of the two. Images
are representative of 10 to 16 cells per time point, per experiment, from three (EEA1) or four
(LAMP1) independent experiments. Bar, 10 µm.
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Figure 3.6 α7 nAChR-αBTX complexes traffic through late endosomes/lysosomes but
not rapidly or slowly recycling endosomes or Rab5 positive early endosomes.
HEK 293 cells co-transfected with cDNA for FLAG-α7 nAChR, HA-hRIC3, and GFP-Rab4 (rapidly
recycling endosomes), GFP-Rab5 (early endosomes), GFP-Rab7 (late endosomes/lysosomes), or
GFP-Rab11 (slowly recycling endosomes) were incubated at 37 °C in the presence of Alexa Fluor
647-αBTX for 2 h. The cells were washed, fixed and mounted and images of Alexa Fluor 647αBTX (green) and GFP (red) were collected from single z-sections on a laser-scanning confocal
microscope and colour combined. Insets show magnified images of the areas indicated by an
arrowhead for Alexa Fluor 647-αBTX (green) with GFP-tagged RabGTPases (red) and an overlay
of the two. Images are representative of 5 to 10 cells per experiment, from two independent
experiments. Bar, 10 µm.
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Knowledgebase reference P36544 (UniProt Consortium). From this sequence, I
identified two short amino acid sequences that represent putative trafficking motifs that
could be involved in regulating cell surface expression or endocytosis of the α7 nAChR
(Figure 3.7 A). The sequence 386YIGF389 fits the profile of a YXXØ (Y, tyrosine; X, any
amino acid, Ø, amino acid with a bulky hydrophobic side chain) signal that binds the μ
subunits of adaptor protein complexes and mediates rapid internalization from the
plasma membrane and can target proteins to the lysosome (62). The sequence
417DEHLL421

is similar to the DXXLL signal present in transmembrane proteins that cycle

between the trans-Golgi network and endosomes and bind the clathrin adaptor
proteins, Golgi-localized, γ-ear-containing, ADP-ribosylation factor-binding proteins (62).
We used site-directed mutagenesis to generate mutant isoforms of the FLAG-α7 nAChR
subunit containing the mutations Y386A/F389A, Y386F/F389A, L420A/L421A, or
D417A/L420A/L421A, then compared αBTX-induced internalization of these mutants to
that of wild-type FLAG-α7 nAChR in HEK 293 cells co-transfected with HA-hRIC3 cDNA
(Figure 3.7 B, C, and D). Mutations to these sequences did not appear to alter cell
surface expression or αBTX-induced internalization of the α7 nAChR, as cell surface antiFLAG immunofluorescence and the internalization of fluorescent αBTX did not appear to
differ between wild-type and mutant isoforms of the receptor after 0, 4, or 6 h at 37 °C.
This demonstrates that these two motifs do not play a role in the trafficking of α7
nAChR to the cell surface in HEK 293 cells or prevent αBTX-induced internalization of the
receptor in these cells.

3.4.5

Endocytosis of α7nAChR-αBTX Complexes is Independent of
Clathrin

Some ligand-gated ion channels are internalized by a clathrin- and dynamin-dependent
endocytic mechanism (19, 20, 63, 64). Transferrin receptor internalization is
characteristic of the clathrin- and dynamin-dependent receptor endocytosis pathway
(65 - 68). Calthrin- and dynamin-dependent receptor endocytosis can be blocked by the
dominant negative mutant isoform of dynamin, dynamin K44A, and the carboxylterminal fragment of adaptor protein 180 (AP180-C) (69 - 71). GTPase defective
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Figure 3.7 Canonical endocytic receptor trafficking motifs do not alter cell surface
expression or endocytosis of α7 nAChR.
(A) Putative trafficking motifs were identified within the amino acid sequence of the large
intracellular loop of the α7 nAChR subunit between TM3 and TM4, highlighted in red in the
schematic. 386YIGF389 (green) may represent a signal that binds the μ subunit of adaptor protein
complexes and mediates rapid clathrin-dependent internalization from the plasma membrane.
417DEHLL421 (yellow) may represent a signal that regulates cycling between the trans-golgi
network and endosomes through binding GGA clathrin adaptor proteins. (B, C, and D) HEK 293
cells were transfected with cDNA for HA-hRIC3 and (B) wild-type FLAG-α7 nAChR or isoforms of
FLAG-α7 nAChR containing mutations to (C) the putative adaptor protein binding motif 386YIGF389
(Y386A/F389A or Y386F/F389A) or (D) the putative GGA binding motif 417DEHLL421 (L420A/L421A
or D417A/L420A/L421A). (A, B and C) Cells were incubated on ice for 1 h with Alexa Fluor 647αBTX, washed and transferred to 37 °C for 0, 4, or 6 h. At the end of the incubation, the cells
were stained to detect changes to surface levels of FLAG-α7 nAChR as described in Fig. 2.
Images are representative of 5 to 20 cells per time point, per experiment, from three
independent experiments. Bar, 10 µm.
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dynamin K44A inhibits the budding of clathrin vesicles from the plasma membrane (69,
70). AP180-C inhibits the formation of clathrin-coated pits that facilitate receptor
internalization (71). Dynamin K44A and AP180-C both block transferrin receptor
endocytosis (69 - 71). To determine if α7 nAChR-αBTX complexes undergo clathrindependent endocytosis, we examined internalization of fluorescent αBTX in cells cotransfected with FLAG-α7 nAChR and HA-hRIC3 cDNA and either dynamin 1 K44A or
AP180-C (Figure 3.8). HEK 293 cells were transfected, incubated with fluorescent αBTX
on ice and transferred to 37 °C for 6 h. To assess functional expression of dynamin 1
K44A or AP180-C protein, a fluorescent di-ferric transferrin conjugate was added to the
cell culture medium 20 minutes prior to the end of the experiment. Cells co-expressing
dynamin 1 K44A or AP180-C were indicated by a lack of fluorescent transferrin
internalization; internalization of fluorescent αBTX was unaffected in these cells (Figure
3.8 A and B). We conducted four independent experiments on cells co-transfected with
dynamin 1 K44A or AP180-C and employed transferrin internalization in our final
experiment as a measure of the functional expression of these proteins; in any of the
experiments we conducted we did not observe inhibition of fluorescent αBTX
internalization. This suggests that the endocytosis of α7 nAChR-αBTX complexes does
not occur through a clathrin- or dynamin-dependent mechanism.

3.4.6

Inhibition of Actin Dynamics, RhoGTPases or RalGTPase Does Not
Block α7 nAChR Endocytosis

Clathrin-independent endocytic mechanisms can induce changes to the actin
cytoskeleton to facilitate endocytosis (72 - 74). We investigated the role of actin
polymerization in the endocytosis of α7 nAChR-αBTX complexes by treating cells with
cytochalasin D. Cytochalasin D is a plasma membrane-permeable inhibitor of actin
polymerization that binds to the ends of actin filaments and prevents the addition of
monomers (75). HEK 293 cells transfected with FLAG-α7 nAChR and HA-RIC3 cDNA were
incubated on ice with fluorescent αBTX and transferred to 37 °C for 2 or 4 h in the
presence of 2.5 μM cytochalasin D or an equivalent concentration of DMSO vehicle. To
label FLAG-α7 nAChR remaining in the plasma membrane, cells were returned to ice and
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Figure 3.8 Endocytosis of α7 nAChR-αBTX complexes is independent of clathrin.
HEK 293 cells transfected with cDNA for FLAG-α7 nAChR and HA-hRIC3, and either (A) dominantnegative dynamin 1 K44A or (B) the C-terminal fragment of the adaptor protein AP180 (AP180C) were incubated on ice for 1 h with Alexa Fluor 647-αBTX (green), washed, and transferred to
37 °C for 6 h. Twenty minutes before the end of the experiment, Alexa Fluor 633-transferrin
(red) was added to the cell culture medium. For A and B , images are representative of 10 to 12
cells per time point, two cover slips per time point, from four independent experiments. Bar, 10
µm.
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incubated with anti-FLAG antibody and fluorescent secondary antibody. Cytochalasin D
clearly disrupted actin cytoskeleton dynamics, as evidenced by changes in cell
morphology, but did not prevent the internalization of fluorescent αBTX (Figure 3.9 A).
DMSO treatment did not affect cell morphology or internalization of fluorescent αBTX
(Figure 3.9 A).
Rho family GTPases regulate actin dynamics and may function in distinct pathways of
clathrin-independent endocytosis (72 - 74). We assessed the involvement of
RhoGTPases in the internalization of α7 nAChR-αBTX complexes in HEK 293 cells cotransfected with FLAG-α7 nAChR and HA-RIC3 cDNA and cDNA for GFP-tagged dominant
negative isoforms of the RhoGTPases, RhoA, Rac1, and Cdc42. Co-expression of RhoA
T19N, Rac1 T17N, or Cdc42 T17N, did not prevent the internalization of fluorescent
αBTX after 4 h at 37 °C (Figure 3.9 B).
RalA is a member of the Ras family of GTPases which plays a role in the endocytosis of a
variety of receptors and can act upstream of Rac1 and Cdc42 to affect actin dynamics
(76, 77). We examined internalization of fluorescent αBTX in HEK 293 cells cotransfected with FLAG-α7 nAChR and HA-RIC3 cDNA and cDNA for a yellow fluorescent
protein (YFP)-tagged dominant negative isoform of RalA, RalA S28N (78, 79). Coexpression of RalA S28N did not prevent internalization of fluorescent αBTX after 4 h at
37 °C (Figure 3.9 B). These results suggest that inhibition of actin dynamics or small
GTPases that regulate actin polymerization to facilitate endocytosis do not play a role in
the internalization of α7 nAChR-αBTX complexes.

3.4.7

α7 nAChR-αBTX Complexes Endocytose Through Flotillin 1 and
Caveolin 1α Pathways

Flotillin 1 and caveolin 1α are components of distinct pathways of clathrin-independent
endocytosis that, in addition to clathrin, indicate separate plasma membrane regions
involved in internalization (72, 80, 81). To determine the involvement of these proteins
in the internalization of α7 nAChR-αBTX complexes, we examined localization of
fluorescent αBTX and GFP-tagged flotillin 1 or caveolin 1α in HEK 293 cells. Cells
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Figure 3.9 Inhibition of actin dynamics, RhoGTPases or RalGTPase does not block α7
nAChR endocytosis.
(A) HEK 293 cells transfected with FLAG-α7 nAChR and HA-hRIC3 cDNA were incubated on ice
with Alexa Fluor 647-αBTX for 1 h, washed, and then transferred to 37 °C in the presence of
cytochalasin D or DMSO vehicle for 2 or 4 h. At the end of the incubation, the cells were
returned to ice and incubated with anti-FLAG antibody to label cell surface receptors, followed
by Alexa Fluor 546-conjugated secondary antibody. Cells were fixed with PLP, mounted, and
images of Alexa Fluor 546-conjugated secondary antibody (red) and Alexa Fluor 647-αBTX
(green) were collected from single z-sections on a laser-scanning confocal microscope. (B) HEK
293 cells co-transfected with cDNA for FLAG-α7 nAChR, HA-hRIC3, and YFP- or GFP-tagged
dominant-negative mutant isoforms of RhoGTPases (RhoA T19N, Rac1 T17N, and Cdc42 T17N)
or RalGTPase (RalA S28N) were labelled with Alexa Fluor 647-αBTX as in A and chased at 37 °C
for 4 h. Cells were fixed with PLP, mounted, and images of Alexa Fluor 647-αBTX (green) and
YFP or GFP (red) were collected from single z-sections on a laser-scanning confocal microscope.
For A, images are representative of 10 to 18 cells per time point, per treatment, per experiment,
one to two cover slips per time point, from two independent experiments; for B, 5 to 17 cells,
per treatment, per experiment, from four independent experiments. Bar, 10 µm.
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Figure 3.10 α7 nAChR-αBTX complexes internalize through flotillin 1 and caveolin 1α
pathways.
HEK 293 cells transfected with cDNA for FLAG-α7 nAChR, HA-hRIC3, and either (A) flotillin 1-GFP
or (B) caveolin 1α-GFP were incubated on ice for 1 h with Alexa Fluor 647-αBTX, washed and
transferred to 37 °C for 2 h. Cells were fixed and mounted and images of Alexa Fluor 647-αBTX
(green) and flotillin 1-, or caveolin 1α-GFP (red) were collected from single z-sections on a laserscanning confocal microscope and colour combined. Insets show magnified images of the area
indicated by an arrowhead for Alexa Fluor 647-αBTX (green) with flotillin 1-, or caveolin 1α-GFP
(red) and an overlay of the two. Images are representative of 41 cells for A (flotillin 1-GFP) and
42 cells for B (caveolin 1α-GFP) from a preliminary experiment. Bar, 10 µm.
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transfected with FLAG-α7 nAChR, HA-hRIC3 and GFP-tagged flotillin 1 or GFP-tagged
caveolin 1α cDNA were incubated on ice with fluorescent αBTX and transferred to 37 °C
for 2 h (Figure 3.10 A and B). Co-localization of fluorescent αBTX with flotillin 1 or
caveolin 1α, in punctate structures, was apparent in nearly all cells we observed. This
suggests that these two proteins may represent pathways for internalization of
α7 nAChR-αBTX complexes from the plasma membrane.

3.5 Discussion
Knowledge of mechanisms that regulate surface expression, endocytosis, or trafficking
of α7 nAChR is currently limited. Some studies have identified specific sequences within
the large intracellular loop of the α7 nAChR subunit that regulate the assembly of
receptors and their insertion into the plasma membrane (82 - 84). Others have
determined the necessity for post-translational modification (85) or the expression of
tissue-specific component proteins, such as the chaperone protein hRIC3 (27), for
functional expression of the α7 nAChR at the cell surface. Additional studies have
determined a role for SNAREs, proteins that mediate vesicular fusion (86), in the
dynamic cycling of the receptor in response to agonist stimulation (87) or tyrosine
kinase activity (88). However, endocytic mechanisms that regulate cell surface levels of
the α7 nAChR have yet to be described. In this study, we demonstrate that binding of
the competitive antagonist αBTX induces internalization of the α7 nAChR and present a
potential pathway for the traffic of α7 nAChR-αBTX complexes to degradative
compartments of the cell.
We began our investigation by verifying that co-expression of the chaperone protein
hRIC3 is required for functional expression of the α7 nAChR in HEK 293 cells. Our
immunocytochemistry and biotinylation findings are in agreement with Williams et al.
(27), in demonstrating that α7 nAChR can be expressed on the surface of HEK 293 cells
in the absence of hRIC3, but that co-expression of hRIC3 with the α7 nAChR is required
for αBTX binding. hRIC3 appears to be necessary for proper assembly of the α7 nAChR
and functional expression of the receptor on the surface of HEK 293 cells.
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We first compared αBTX-induced internalization of the α7 nAChR in HEK 293 cells with
SH-SY5Y cells, a cell line with a neuronal phenotype (89, 90) that endogenously
expresses hRIC3 (27). αBTX induced internalization of the α7 nAChR in both HEK 293
and SH-SY5Y cells, lead to the accumulation of α7 nAChR-αBTX complexes in perinuclear
regions after several hours. Cell surface levels of the receptor following αBTX-induced
internalization appeared to be down-regulated in HEK 293 cells over time, but similar
changes were not observed in SH-SY5Y cells, perhaps due to the relative efficiency of
receptor assembly exhibited by these two cell types (82). Although SH-SY5Y cells
internalized αBTX at a rate similar to HEK 293 cells, SH-SY5Y cells may have a greater
reserve of fully assembled receptors to replace those lost from the cell surface (82). In a
preliminary experiment to examine the replacement of receptors on the surface of HEK
293 cells, we induced receptor internalization with unlabelled αBTX and stained for
newly emerged receptors after 6 h. Only a fraction of cells showed a small amount of
fluorescent αBTX labelling, suggesting that insertion of α7 nAChR into the plasma
membrane in HEK 293 cells was a slow process. This also suggests that, when we are
labelling cell surface receptors with anti-FLAG antibody and fluorescent secondary
antibody to determine changes to cell surface levels, we are likely labelling receptors
that remained on the surface of HEK 293 cells and have not yet internalized.
Following internalization, α7 nAChR-αBTX complexes trafficked to lysosomes from EEA1positive early endosomes and Rab7-positive late endosomes. α7 nAChR-αBTX
complexes transitioned from early endosomes to lysosomes from between 2 to 4 h and
all internalized αBTX appeared to be in LAMP1-positive lysosomes after 6 h. This timecourse is similar to that observed for αBTX-mediated down-regulation of the muscle
nAChR in CHO cells (91). We did not find co-localization of αBTX with Rab 4 or Rab11positive vesicles, suggesting that, once internalized, α7 nAChR complexes are not
recycled back to the cell surface; rather they appear to be trafficked directly through
Rab7-positive late endosomes to lysosomes for degradation. These results are in
contrast to Kumari et al. (91), who observed that some muscle nAChR-αBTX complexes
co-localized with Rab11; there is some evidence to suggest that αBTX-labelled nAChR
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undergoes dynamic recycling at the neuromuscular junction (92, 93). Internalized αBTX
did not co-localize with Rab 5, which seems to contradict with our observation that
αBTX traffics through EEA1-positive vesicles early in the stages of receptor
internalization. Although EEA1 is an important Rab5 effector, required for mediating
fusion of early endosomes (50), it is evident that EEA1 can tether to endosomes
independently of Rab5 (94).
The cell surface expression of several ionotropic receptors can be regulated by signal
sequences contained within their cytosolic domains (63, 95 - 98). To determine whether
the α7 nAChR could be regulated in a similar manner, we identified two putative motifs
that fit the criteria of sorting signals recognized in a large number of transmembrane
proteins, 386YIGF389, and 417DEHLL421. Mutations to these signal sequences can lead to
increased surface expression of the relevant receptors, as a result of the disruption of
adaptor protein binding and the prevention of clathrin-mediated endocytosis (63, 95,
96, 98). When we generated mutant isoforms of the α7 nAChR and compared their cell
surface expression and αBTX-induced internalization to the wild-type protein, we did
not observe a substantial difference between wild-type and mutant, demonstrating that
386YIGF389

and 417DEHLL421 sequences do not regulate cell surface expression of the

receptor or alter αBTX-induced internalization.
To delineate a mechanism that regulates αBTX internalization, we investigated factors
that are specific to clathrin-dependent and -independent endocytosis. The
ineffectiveness of over-expression of dominant-negative dynamin 1 K44A and AP180-C
demonstrate that αBTX induced internalization of the α7 nAChR is a dynamin- and
clathrin-independent process. αBTX induced internalization of the α7 nAChR was not
affected by treating cells with an inhibitor of actin polymerization, cytochalasin D, or
over-expression of dominant negative isoforms of the RhoGTPases, RhoA, Rac1, or
Cdc42, or over-expression of dominant negative RalA, suggesting that clathrinindependent mechanisms that recruit changes to the actin cytoskeleton and activity of
these GTPases to facilitate endocytosis did not mediate this process. It appears that
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internalization of α7 nAChR-αBTX complexes occurs independently of clathrin and
dynamin, as well as cytoskeleton dynamics and RhoGTPase activity. In comparison,
Kumari et al. (91) found that αBTX-induced internalization of the muscle nAChR was
independent of dynamin, but required both actin polymerization and Rac1 activity.
Both systems involve heterologous expression of nAChR, as HEK 293 cells and CHO cells
do not endogenously express these proteins. However, the muscle nAChR is highly
organized at neuromuscular junctions where coupling to the actin cytoskeleton
maintains synaptic integrity (99, 100). In contrast, the α7 nAChR is expressed at
perisynaptic and somatic locations (2 - 5, 7 - 12) and appear to function independently
of cytoskeleton dynamics (101). Therefore, actin dynamics may not play a role in the
internalization of the α7 nAChR in response to binding αBTX.
Clathrin-independent endocytosis can occur from lipid rafts within the plasma
membrane that are enriched in either caveolins (caveolae) or flotillins (72, 80, 81). αBTX
co-localized with flotillin 1 and caveolin 1α puncta after internalization was allowed to
proceed for 2 h, a time point at which αBTX is co-localized with EEA1 and in the process
of becoming internalized. This suggests that flotillin 1 or caveolin 1α-associated
pathways may represent mechanisms for endocytosis of α7 nAChR-αBTX complexes. It
is currently hypothesized that caveolins and flotillins represent distinct pathways for
endocytosis (72, 80, 81). Despite this, it is apparent that the α7 nAChR can associate
with either caveolin- or flotillin-positive lipid rafts, depending on the cell type (101, 102).
This has also been demonstrated here.
HEK 293 cells endogenously express caveolins at negligible levels relative to their level
of flotillin expression (103, 104). Caveolar-mediated endocytosis requires dynamin
GTPase activity (105, 106), while flotillin-mediated endocytosis can occur both
dependently (107, 108) and independently of dynamin (81). Given that we observed
internalization of αBTX was not blocked by a dominant-negative isoform of dynamin, it
seems likely that endocytosis of α7 nAChR-αBTX complexes occurs through a flotillinassociated pathway. However, since we observed co-localization of internalized αBTX
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with both markers, endocytosis of the α7 nAChR through these pathways could be
determined by the level of expression of caveolin and flotillin protein or the relative
affinity of the receptor for localization to caveolae versus flotillin-enriched lipid rafts,
which is currently unknown. Fractionation of intact cells followed by density gradient
centrifugation is a widely used technique for separating subcellular membrane
compartments, such as endocytic vesicles, for identifying subcellular organelles through
which proteins traffic (109). Fractionation of transfected HEK-293 or SH-SY5Y-FLAG-α7
cells and density gradient centrifugation, following pulse-chase with αBTX, combined
with immunoblotting for flotillin or caveolin (102) and FLAG epitope could have
provided biochemical evidence in support of our localization experiment and help
answer these questions.
We present here evidence in support of an endocytic pathway for the internalization of
α7 nAChR in response to binding an irreversible competitive antagonist, αBTX. We
propose a model in which αBTX induces internalization of the α7 nAChR alternatively
through flotillin- or caveolin-associated endocytosis and trafficking of α7 nAChR-αBTX
complexes through early and late endosomes to lysosomes (Figure 3.11). This occurs
independently of clathrin, dynamin, actin polymerization, or RhoGTPase and RalGTPase
activity and appears to be unique amongst ligand-gated ion channels.
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Figure 3.11 A Model for αBTX-induced internalization of the α7 nAChR.
αBTX binding induces endocytosis of α7 nAChR through alternate flotillin 1- or caveolin 1αassociated pathways and subcellular trafficking through EEA1-positive early endosomes and
Rab7-positive late endosomes to LAMP1-positive lysosomes. Legend, inset.
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4.1 Conclusions

4.1.1

Study One: Oligomeric aggregates of amyloid β peptide 1-42
activate ERK/MAPK in SH-SY5Y cells via the α7 nicotinic receptor

1) Aβ42 peptides aggregate into different structural forms under neutral and acidic
pH. Neutral pH yields small globular oligomeric aggregates, with 3.0 to 3.8 nm
height structures in abundance. Acidic pH yields elongated fibrillar structures tens
of nanometres in length, comprised of oligomer-like subunits.
2) Oligomeric aggregates of Aβ42 acutely activate the ERK/MAPK signalling pathway in
human neuroblastoma cells at concentrations as low as 1 nM.
3) Fibrillar aggregates or non-aggregated Aβ42 peptide do no activate the ERK/MAPK
signalling pathway.
4) Activation of ERK/MAPK by oligomeric Aβ42 is inhibited by MLA, an antagonist
selective for the α7 nAChR.

4.1.2

Study Two: The α7 nicotinic receptor is internalized via a clathrinindependent, flotillin- or caveolin-associated endocytic pathway

1) Binding of the competitive antagonist αBTX causes internalization of the α7 nAChR.
2) Internalized α7 nAChR-αBTX complexes traffic through early and late endosomes to
lysosomes.
3) Internalization is independent of clathrin and dynamin, and is not blocked by
inhibition of actin polymerization or dominant negative RhoGTPases or dominant
negative RalGTPase.
4) Flotillin 1 or caveolin 1α may represent pathways for endocytosis.
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4.2 Contributions to the Current State of Knowledge
The aim of the studies described in this thesis was to enhance our knowledge of the
interaction of Aβ42 peptides with the α7 nAChR as well as factors which may regulate
α7 nAChR function. We present two distinct aspects of α7 nAChR physiology; we
identify a biologically important species of oligomeric Aβ42 peptide aggregate capable
of inducing signalling through the α7 nAChR, and we determine a pathway for regulation
of cell surface levels of the receptor in response to antagonist-induced receptor
internalization.
In the study in Chapter 2, we compared the ability of different aggregates of Aβ42
peptide to activate the ERK/MAPK signalling pathway. Following a previously
established protocol, we pre-incubated synthetic Aβ42 peptide to induce the formation
of oligomers or fibrils. Characterization by AFM demonstrated that these preparations
primarily contained oligomeric or fibrillar aggregates of Aβ42 (Chapter 2, Figure 2.1).
Oligomeric aggregates of Aβ42 acutely activated ERK/MAPK at concentrations within
the range of Aβ42 measured in the CSF of AD subjects. Fibrillar aggregates or nonaggregated Aβ42 did not activate ERK/MAPK. Induction of ERK1/2 phosphorylation by
oligomeric Aβ42 was inhibited by the α7 nAChR-selective antagonist, MLA. In addition
to fibrils, we observed a subpopulation of oligomers 2 nm in height, in fibrillar
preparations. In oligomeric preparations, structures 3.0 - 3.8 nm in height were the
most abundant, representing a biologically important oligomeric aggregate of Aβ42
capable of inducing ERK/MAPK signalling through the α7 nAChR.
Since the amyloid cascade hypothesis was proposed by Hardy and Higgins (1),
suggesting that the generation and aggregation of Aβ peptides, particularly Aβ42, were
an initiating event in AD pathogenesis, considerable effort has been made to determine
factors that contribute to the aggregation of these peptides and identify physiologically
relevant species. Numerous studies have used AFM and/or SDS-PAGE to identify
biologically important aggregates of Aβ42 and equate their structure with receptor
binding, cell signalling, toxicity, or membrane disruption. We employed AFM as a
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method for characterizing our preparations because it provided a means for clearly
distinguishing between different structural forms of Aβ42 peptide. Using high
resolution AFM, Mastrangelo and colleagues (2) determined that monomers of Aβ42
peptide have an approximate height of 2 nm. Although the AFM instrument that we
used likely introduced sample compression, thereby underestimating the true height of
aggregates within our samples, we would propose that the globular structures we
observed in abundance in oligomeric preparations of Aβ42, with a height of 3.0 - 3.8 nm,
were representative of dimers of Aβ42 peptide. Also, given the distribution of
aggregate sizes we observed, with subpopulations residing between 1.2 and 4.4 nm,
that our oligomeric preparations contained a mixture of monomers and dimers.
In our fibrillar preparations of Aβ42 peptide, we observed a subpopulation of
oligomeric-like aggregates that appeared to represent distinct subunits of the greater
fibrils. A recent study in a transgenic mouse model has proposed that plaques of Aβ42
in the brain may act as reservoirs for the release of Aβ42 oligomers (3). Plaques are
thought to be primarily composed of Aβ42 fibrils (4), our AFM analysis appears to
support the hypothesis that these fibrils can disassemble into oligomeric species.
Aβ peptides have previously been observed to activate the ERK/MAPK signalling
pathway through α7 nAChR in hippocampus (5). An age-dependent increase in
α7 nAChR protein and coincident reduction in phosphorylated ERK2 protein in this brain
region in a transgenic mouse model of AD may be a consequence of increased Aβ
burden and the resulting chronic activation of α7 nAChR-dependent signalling (5). The
down-regulation of α7 nAChR-dependent signalling is hypothesized to be a cellular
mechanism that contributes to AD pathology (5). Given the evidence that α7 nAChR
largely plays a modulatory role in neurotransmission in the brain, by regulating the
release of neurotransmitters (6 - 11), Aβ peptides likely have a complementary
consequence in early stages of the disease process. Neurotransmitter release is
enhanced by α7 nAChR signalling through ERK/MAPK and increased ERK1/2-dependent
phosphorylation of the synaptic vesicle co-ordinating protein, synapsin-1 (8), which
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increases the proportion of vesicles available for release in the synaptic terminal (12). I
would propose that oligomeric Aβ42 may signal through α7 nAChR and ERK/MAPK, as
we have observed here, to synapsin-1 to alter activity of the neural network in the
absence of cholinergic input, thereby contributing to disordered cognitive function in
AD.
In the study described in Chapter 3, we investigated the pathway for internalization of
the α7 nAChR in response to binding the competitive antagonist, αBTX. αBTX binding
induced internalization of α7 nAChR-αBTX complexes that trafficked through early and
late endosomes and accumulated in lysosomes (Chapter 3, Figure 3.4). Primary amino
acid sequence analysis revealed two potential clathrin adaptor protein binding motifs
within the large intracellular loop of the α7 nAChR subunit. Site-directed mutagenesis
experiments revealed these motifs did not alter internalization or subcellular trafficking
of α7 nAChR-αBTX complexes. Experiments employing over-expression of dominant
negative dynamin 1 K44A or AP180-C did not block internalization, providing further
evidence that internalization was independent of the clathrin endocytic machinery.
Subsequent experiments, in which we disrupted clathrin-independent mechanisms of
endocytosis, employing cytochalasin D to inhibit actin-polymerization or overexpression of dominant negative RhoGTPases or RalGTPase, did not have an effect on
internalization either. Ultimately, co-localization experiments with flotillin 1 and
caveolin 1α revealed that these two lipid raft proteins represented pathways for
endocytosis (Chapter 3, Figure 3.9). These experiments are the first to report
internalization of the α7 nAChR in response to binding αBTX and identify lipid raft
proteins as the potential mediators.
Caveolins and flotillins represent distinct pathways for endocytosis (13 - 15) and are
associated with separate lipid microdomains within the plasma membrane (15 - 19).
These integral membrane proteins are differentially expressed and cell types that do not
express caveolins often express flotillins as functional homologues in the organization of
caveolae-like lipid rafts (19). The α7 nAChR can be found in either caveolin- or flotillin-
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positive lipid microdomains depending on the cell type (20, 21). However, caveolins are
not expressed by brain neurons and flotillins are thought to be the primary integral
membrane proteins associated with cholesterol-rich microdomains in brain neuronal
plasma membranes (18, 22, 23). This evidence indicates that floltillins could represent
the pathway for endocytosis of the α7 nAChR in the brain.
An important parallel can be drawn between factors that mediate endocytosis of
flotillins and those which alter cell surface levels of the α7 nAChR. Endocytosis of
flotillin 1 and flotillin 2 is regulated by activation of the tyrosine kinase, Fyn, leading to
the redistribution of flotillins from the plasma membrane to late endosomes and
lysosomes (24). Cell surface levels of the α7 nAChR in hippocampal neurons appear to
be negatively regulated by tyrosine kinase activity that does not involve direct
phosphorylation of the receptor, with tyrosine phosphorylation depressing α7 nAChR
responses in brain slices to agonist stimulation (25).
Additionally, there is a relationship between the level of flotillin expression in the brain
and the progression of AD, as flotillin levels increase with the development of senile
plaque formation and the advancement of disease pathology (26). Increased Aβ42
peptide production in transgenic mice leads to intracellular accumulation of Aβ42
peptide in flotillin 1-positive endocytic vesicles (27). Aβ production appears to require
flotillin-dependent clustering of the Aβ42 precursor protein, APP, which promotes
endocytosis and subsequent processing of APP into Aβ peptides (28). Increased levels
of [3H]-MLA binding as a measure of α7 nAChR protein in the frontal cortex are weakly
correlated with Aβ plaque pathology in human subjects in the early stages of AD (29).
Given the controversy surrounding the interaction between Aβ42 peptides and the
α7 nAChR, a shared pathway of endocytosis may account for some observations that
the α7 nAChR mediates internalization of Aβ42 peptides in neuronal cells (30).
Interestingly, a GPI-anchored cell surface molecule, lynx1, with a structure notably
similar to αBTX and other elapid snake α-neurotoxins, has been identified in the brain
(31). Lynx1 co-localizes with the α7 nAChR in many regions, including cortex,
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hippocampus, amygdala, and thalamus (32). Studies in lynx 1 knock-out mice have
revealed that lynx1 expression increases sensitivity of nAChRs to agonist stimulation,
alters synaptic activity in the hippocampus, and enhances sensitivity of neurons to
excitotoxicity, leading to neurodegeneration (33). Recombinant expression of αBTX in
cells as a plasma membrane-tethered protein, as a model for lynx1 activity, retains its
functions as an antagonist (34). Endogenous α-neurotoxin-like macromolecules in the
brain may have a role in regulating α7 nAChR function.

4.3 Limitations of Research
The characterization of specific aggregate species of Aβ42 peptides of particular
biological relevance is a persistent and challenging problem. Although analysis by SDSPAGE has been frequently used to characterize Aβ42-containing solutions, this analysis
does not reflect the nature of aggregates found in solution (35). AFM analysis relies
upon the ability of samples to adsorb to the surface of a mica substrate. All species of
aggregates within a solution containing Aβ42 peptides may not be equally adsorbed to
mica, thereby providing a misrepresentation of the true nature of the solution state of
the peptide (36). Attempts have been made to circumvent these issues (35), but it is
apparent that aggregates of Aβ42 peptide in solution are likely in dynamic equilibrium
and one can only infer from the method of analysis as to the true nature of the
aggregates. However, AFM has been established as and remains a method for
consistently discriminating between solutions containing oligomeric and fibrillar
aggregates of Aβ42 peptide (37).
Conducting experiments to examine the trafficking of transmembrane proteins is limited
by evidence that demonstrates inhibition of one pathway for endocytosis, through over
expression of dominant negative proteins for example (38), can lead to the upregulation of an alternative endocytic mechanism. We have tried to overcome this by
examining pathway specific markers in conjunction with the over-expression of
dominant negative proteins; by comparing localization of internalized αBTX with that of
transferrin, in the presence and absence of dominant negative proteins that disrupt
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clathrin-dependent endocytosis. We also sought to examine the localization of
endogenous proteins, EEA1 and LAMP1, to avoid artefacts that heterologous overexpression can create.
Experiments conducted in cell lines are not ideal, due to the possibility that cellular
pathways or signalling mechanisms can be disrupted in comparison to their function in
primary culture or in vivo (14). However, hippocampal neurons express limited amounts
of α7 nAChR at the plasma membrane (39), and cell lines, as a model, often provide
greater transfection efficiency and greater protein expression levels from which to
ascertain clues as to how such proteins of low abundance may be regulated.

4.4

Suggestions for Future Studies

Many models have been proposed for the binding of Aβ42 peptides to the α7 nAChR (40
- 42). However, the identification of a specific n-mer of Aβ42 peptide that binds to the
α7 nAChR as a ligand has yet to be identified in biochemical experiments. MALDI mass
spectrometry of nAChR subunits has been performed successfully (43, 44). Cross-linking
of α7 nAChR and bound Aβ42 peptide oligomers, followed by MALDI mass spectrometry
of these isolated complexes could provide a definitive answer as to the composition of
these oligomers.
Further studies would be necessary to fully elucidate the mechanism of αBTX-induced
internalization of the α7 nAChR. Knock-down of endogenous caveolin or flotillin
expression through transfection with siRNA (15, 45) could determine if these lipid raft
proteins were required for receptor internalization. Immunostaining with antibody
directed against endogenous flotillin (19), in conjunction with the same for endogenous
endosomal and lysosomal markers, such as EEA1 and LAMP1, to determine their
localization with internalized α7 nAChR-αBTX complexes, could determine if flotillin and
the α7 nAChR traffic together through intracellular membrane compartments.
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4.5 Significance of the Research
The studies presented in this thesis further our knowledge of distinct aspects of
α7 nAChR physiology. Oligomeric aggregates of Aβ42 peptide are identified as the
principal structural form of the peptide capable of activating intracellular signalling
through the α7 nAChR. This has direct implications in AD pathology in that it reinforces
the widely held hypothesis that small oligomers of Aβ42 peptide, rather than Aβ42
fibrils, represent the biologically active form of the peptide and that oligomeric Aβ42mediated signalling through α7 nAChR may play a role in the disease process. The
studies also describe internalization of the α7 nAChR in response to binding the
competitive antagonist, αBTX. This is the first time antagonist-induced internalization of
the α7 nAChR has been reported. A unique pathway for endocytosis of the receptor is
proposed, providing new insight into mechanisms that can regulate cell surface
expression of the receptor.
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Appendix A. Addition of the FLAG epitope to the α7 nAChR subunit slows receptordependent Ca2+ responses to the agonist nicotine.
(A – C) HEK 293 cells co-transfected with cDNA for HA-hRIC3 and either wild-type α7 nAChR or
FLAG-α7 nAChR subunit were loaded with the Ca2+-sensitive dye fura-2, perfused with HEPES
buffered Krebs-Ringer’s solution, and whole-cell fluorescence emission of fura-2 (510 nm) was
monitored at alternating excitation wavelengths (345 and 380 nm). An increase in the ratio of
fluorescence emission at excitations 345 / 380 nm indicated an increase in intracellular Ca2+.
Nicotine (1 mM) was applied for 0.5 s (arrowhead). The α7 nAChR antagonist MLA (10 µM) was
included in perfusion buffer prior to application of nicotine (+ MLA). (A) Changes observed in
five different HEK 293 cells transfected with wild-type α7 nAChR subunit and HA-hRIC3 cDNA.
Tracings are superimposed to illustrate the variability in responses observed between cells and
between transfections. Average tracing from 20 cells (red). (B) Changes observed in five
different cells transfected with FLAG-α7 nAChR subunit and HA-hRIC3 cDNA. Average tracing
from 30 cells (red). (C) Time to peak response as measured by the difference between the time
of application of nicotine and the time when fluorescence ratio reached maximum. Bars
represent mean ± SEM, n = 20 cells for wild-type α7 nAChR subunit and n = 30 cells for FLAGα7 nAChR subunit, from four independent experiments.

153

154

Appendix B. Cell surface biotinylation of HEK 293 cells transfected with FLAGα7 nAChR cDNA with or without co-transfection with HA-hRIC3 cDNA.
HEK-293 cells were transfected with FLAG-α7 nAChR cDNA and empty vector DNA; FLAGα7 nAChR and HA-hRIC3 cDNA, or empty vector DNA and HA-hRIC3 cDNA. Eighteen hours after
transfection, cells were transferred to ice and incubated with EZ-Link sulfo-NHS-SS-biotin (1.5
mg/mL) in HBSS for 1 h. To quench unreacted sulfo-NHS-SS-biotin, cells were subsequently
washed and incubated with chilled HBSS containing glycine (100 mM) for 30 min. Cells were
then lysed and equal amounts of protein from each transfection (400 µg) were made up to
equal volumes in lysis buffer (500 µL) and rotated with NeutrAvidin agarose beads (100 µL of
slurry; biotin binding capacity of 1 - 2 mg/mL) at 4 °C for 1 h to precipitate sulfo-NHS-SS-biotin
bound proteins. NeutrAvidin beads were washed with lysis buffer and biotinylated proteins
were eluted by heating in Laemmli sample buffer. (A) Precipitated biotinylated proteins
immunoblotted with anti-FLAG antibody and HRP-conjugated secondary antibody. Lanes (a) and
(b), HEK 293 cells transfected with FLAG-α7 nAChR subunit cDNA and empty vector DNA; lanes
(c) and (d), cells co-transfected with FLAG-α7 nAChR subunit and HA-hRIC3 cDNA, lanes (e) and
(f), cells co-transfected with empty vector DNA and HA-hRIC3 cDNA. (B) Crude lysate fractions
from lanes (a), (c) and (e), immunoblotted for FLAG epitope. Immunoblots are from a
preliminary experiment.
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Appendix C. De novo cell surface α7 nAChR following αBTX-induced receptor
internalization.
HEK 293 cells transfected with cDNA for FLAG-α7 nAChR and HA-hRIC3 were incubated on ice
for 1 h with unlabelled αBTX, washed, and transferred to 37 °C for 0 or 6 h. At the end of the
incubation, the cells were returned to ice and incubated with Alexa Fluor 647-αBTX for 1 h to
detect the appearance of new receptors on the cell surface. Nuclei were stained with DAPI prior
to fixing and mounting. Images of Alexa Fluor 647-αBTX (green) and DAPI (blue) were collected
from single z-sections on a confocal microscope and colour combined. Images are
representative of 16 to 18 cells per time point, from three cover slips, a preliminary experiment.
Bar, 10 µm.
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